The growth strategies of a global pharmaceutical company : a case study of Aspen Pharmacare Holdings Limited. by Hodgon, Victoria Margaret.




THE GROWTH STRATEGIES OF A GLOBAL PHARMACEUTICAL COMPANY: 









A dissertation submitted in partial fulfilment of the requirements for the 
degree of Master of Business Administration 
 
College of Law and Management Studies 
Graduate School of Business & Leadership 
 
 
Supervisor: Dr. Muhammad Ehsanul Hoque 
 
 





This dissertation is dedicated to Big Jay for her constant encouragement and 
support during my studies and the preparation of this dissertation. 
 
Thanks go to my friends and colleagues for their positive enthusiasm during this 
process.  
 
The guidance and input from my supervisor Dr. Muhammad Ehsanul Hoque is 























The evolution of Aspen Pharmacare Holdings Limited from its origins less than 20 
years ago is a success story worthy of analysis.  Aspen began trading in 1997 as a 
small pharmaceutical business managed out of a suburban house in Durban, 
South Africa and by 2004 had achieved revenues of R2,2 billion.  Aspen has now 
grown to become a global company with offices in approximately 50 locations 
across the world and revenues of R29,5 billion in 2014.  Given the rapid and 
sustained growth achieved by Aspen over the past 11 years (2004 – 2014), the 
main aim of this study was to identify and analyse the growth strategies adopted 
by Aspen over this time period.  The research method used was a descriptive 
study through a single case study of Aspen by analysing secondary data in the 
form of publicly available company reports and presentations, as well as financial 
results, issued by Aspen between 2004 and 2014.  Qualitative data was extracted 
and analysed to determine the growth strategies used by Aspen, whilst certain 
quantitative data was used for illustrative purposes.  The study found that, guided 
by strategic and visionary leadership, Aspen adopted a number of growth 
strategies including (i) organic growth, as a key factor in creating incremental 
value for Aspen and its stakeholders, (ii) inorganic growth, in the form of carefully 
planned and well executed acquisitions aligned to the Group strategy, (iii) 
extending territorial coverage through global expansion, particularly into emerging 
pharmaceutical markets, and (iv) ongoing investment in production capabilities as 
a means of creating a strategic advantage.  Despite the challenges of intense 
competition, restrictive legislation, pressure on medicine prices, currency volatility 
and market specific risks, Aspen has delivered double-digit earnings growth to its 
shareholders for 16 consecutive years.  The study culminates in the development 
and proposal of a sustainable growth model which is intended to be a unique 
contribution to the academic writings on business growth.  It may be used by 
companies (particularly South African pharmaceutical companies) as part of their 
strategic planning process for growth. 
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Introduction and Overview 
 
“Aspen’s success can be attributed to a number of factors, most notably 
innovation and leadership that practices a fine balance between passion and 
logic.  … We had a vision and we have pursued it with both perseverance 
and passion.  I hope that our story inspires future generations of 
entrepreneurs.” 
Stephen Saad, Aspen Group Chief Executive, 
accepting his award for  
Sunday Times Business Leader of the Year in 2012 
 
1.1 Research Title and Introduction 
 
The growth strategies of a global pharmaceutical company:  
a case study of Aspen Pharmacare Holdings Limited. 
 
This dissertation is a case study analysis of Aspen Pharmacare Holdings Limited 
(“Aspen”) with a focus on the growth strategies adopted by the company. 
 
This introductory chapter presents the framework upon which the research and 
preparation of this dissertation was based.  The chapter commences with an 
introduction to Aspen.  This is followed by the problem statement and research 
questions.  Thereafter the aim of the study, the motivation for the study, as well as 
the significance of the research, is explained.  The research methodology 
employed is described and a chapter overview is provided. 
 
1.2 Introduction to Aspen 
 
Aspen is a supplier of branded and generic pharmaceutical products globally as 
well as infant nutritional and consumer healthcare products in selected territories 
(Aspen, 2014).  The company was established in a suburban home in Durban, 
South Africa in 1997.  A year later it listed on the Johannesburg Stock Exchange 
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(“JSE”) (the South African stock exchange) through a reverse listing into Medhold 
Limited (Aspen, 2014).  The following year Aspen acquired South African 
Druggists, the largest South African-owned pharmaceutical company at the time 
(Cairns, 2011), for R2,4 billion in a highly leveraged hostile takeover described as 
a mouse eating an elephant (Tshabalala, 2014). 
 
Fast forward to 2014 when Aspen was the largest pharmaceutical company listed 
on the JSE and one of the top 20 companies listed on this stock exchange, with a 
market capitalisation R136 billion.  As the largest pharmaceutical company in 
Africa and ranked among the top five generic pharmaceutical producers globally 
(as assessed by EvaluatePharma®), the Aspen Group had 26 manufacturing 
facilities at 18 sites on six continents and approximately 10 000 employees, with 
its products reaching more than 150 countries around the world (Aspen, 2014). 
 
In its 2014 Integrated Report, the Aspen Group reported that for 16 consecutive 
years it had delivered sustained double-digit earnings growth to its shareholders, 
with a compound annual growth rate in revenue, operating profit and normalised 
headline earnings per share exceeding 40% for this period (Aspen, 2014). 
 
1.3 Problem Statement 
 
The main purpose of this study was to identify and analyse the growth strategies 
adopted by Aspen during the period from 2004 to 2014.   
 
Businesses and their leaders are faced with a paradoxical challenge.  On the one 
hand creating value, realising profits and achieving growth are all important 
elements in ensuring the survival and success of a business.  On the other hand 
these endeavours also pose some of the greatest challenges to chief executives 






The modern business environment is described as unstable and unpredictable 
(Grant, 2013) and companies find themselves operating in a global environment 
characterised by rapid change, competitive pressures, geopolitical risks, disruptive 
technologies and changing consumer demands (KPMG, 2015).  Business survival 
is dependent on the ability to respond to this challenging social, political and 
natural environment (Grant, 2013). 
 
Business growth is said to be the key to the long term success of a company as it 
is a prerequisite for increasing revenue, profits and shareholder value (Strategic 
Direction, 2006; Bürkner, King and Razali, 2013).  It could thus be argued that 
growth is a business imperative. 
 
There are a number of diverse approaches to growing a company.  Managers are 
thus faced with a number of options to choose from and decisions to make in order 
to achieve sustainable growth (Kuntz, 2014).  A carefully formulated growth 
strategy, appropriate to the company and which takes into account the importance 
of execution and integration, is thus an essential element of business 
management. 
 
The crafting of a strategy is management’s plan on how the business will be run 
and is a commitment to pursue a particular set of actions in order to grow the 
business (Hough et al., 2011).  This involves choosing which activities the 
business will perform, as well as those which it will not perform, deciding whether it 
will compete on price or efficiency, or deciding whether it intends to create a 
position based on a unique advantage (Porter, 1996; Tanwar, 2013). 
 
The formulation and implementation of strategies for achieving and sustaining 
growth is the business management issue which gave rise to the research 
questions addressed in this study. 
 
Given the rapid and sustained growth of Aspen during the period from 2004 to 
2014, the main purpose of this study was to identify and analyse the growth 
strategies adopted by Aspen during this time period.   
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The research questions to be answered by the study were as follows: 
 
1. What growth strategies has Aspen adopted over the past 11 years (2004 – 
2014)? 
2. What challenges has Aspen faced in implementing the growth strategies? 
3. What learnings can other companies take from the case study analysis of 
Aspen?  
 
1.4 Aim of the Study 
 
The global pharmaceutical industry is a large, established and complex industry, 
with a number of stakeholders including governments, pharmaceutical companies 
(both innovator and generic producers), healthcare insurance providers, 
physicians, pharmacists and patients/consumers (Appelt, 2010).  The industry is 
characterised by intense global competition, increasing government and payor 
pressure to reduce costs and demonstrate value, and restrictive legislation 
(Deloitte, 2014). 
 
The aim of this study was therefore to determine how, in the face of this 
challenging marketplace, Aspen succeeded in growing from a small South African 
pharmaceutical company to a multinational company competing in the global 
pharmaceutical industry. 
 
Against this background, the research also sought to identify the specific 
challenges which Aspen faced in implementing the growth strategies.   
 
The study also set out to determine how the case study analysis of Aspen could 
be useful to other companies and, in particular, what learnings other companies 
could take from the findings, based on analytic generalisation. 
 
Finally, using the findings from the case study analysis, the study sought to 
develop a sustainable growth model for use by companies (particularly South 
African pharmaceutical companies) as part of their strategic planning process for 
growth. 
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1.5 Motivation for the Study  
 
The study was motivated by a desire to conduct a detailed analysis of Aspen in the 
hopes of gaining an in-depth understanding of the company and how it had 
achieved its impressive growth. 
 
A personal motivation for the study was an ongoing fascination with the once small 
Durban pharmaceutical company which has grown into a multinational 
organisation competing with players on the global stage.  The entrepreneurial and 
innovative spirit of the founders and leaders of Aspen, and the story of the 
organisation’s growth, makes for fascinating reading for an MBA student. 
 
From an academic perspective, the evolution of Aspen provides rich real life 
examples of many business management topics, such as strategy, supply chain, 
corporate governance, internationalisation, leadership, and corporate culture. 
 
The motivation for the study was therefore to provide an in-depth analysis of 
Aspen by tracking its growth and the strategies employed to achieve such growth.  
It was intended that such research would benefit academics, business students 
and managers in their understanding of the concepts of strategy and growth, 
which are two important themes in the modern business world.  
 
1.6 Significance of the Study  
 
The study contributes to the body of knowledge on business growth strategies, 
particularly in the context of pharmaceutical companies and South African 
companies which have become global market players, as is the case with Aspen. 
 
The study is intended to be unique as the researcher was unable to find a previous 
academic case study in the business management literature, which had been 
conducted on Aspen.  The analysis of company growth in respect of a 
pharmaceutical company was also intended to be a unique contribution in a move 
away from the more frequently conducted studies on companies in the banking, 
telecommunications and mining sectors. 
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The significance of the research is that it provides an in-depth analysis of Aspen’s 
growth and the strategies which it employed to achieve such growth. 
 
Finally, the development of a sustainable growth model, based on the findings in 
the case study analysis of Aspen, provides a unique contribution to the academic 
writings on business growth. 
 
1.7 Research Methodology 
 
The research method used was a descriptive study through a single case study of 
Aspen by analysing secondary data.  Such data consisted of publicly available 
company reports and presentations, as well as financial results, issued by Aspen 
between 2004 and 2014.  Qualitative data was extracted and analysed to 
determine the growth strategies used by Aspen, whilst certain quantitative data 
was used for illustrative purposes.   
 
A case study is considered to be appropriate for use in a descriptive study when 
the aim is to obtain detailed descriptions or explanations and for understanding a 
phenomenon in its real-world context.  
 
Secondary data is data collected by someone else for another purpose and not 
originally collected for the researcher’s specific study (Lee, Lee and Lee, 2013).  
For this study, secondary data in the form of Aspen’s Annual Reports, 
presentations and financial results, which are made publicly available on its 
website, were utilised.   
 
Qualitative data, in the form of words, was extracted from the company’s accessed 
documents and systematically organised and analysed to establish meaningful 
themes or patterns.  Based on these key words, core themes were identified.  
Quantitative data, in the form of numbers, was also extracted from the company’s 
accessed documents.  Selected figures were collated and converted into graphs 
for analysis and illustrative purposes. 
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This first stage of the case study was aimed at identifying relationships, concepts 
and sequences of events which could assist with arriving at findings in respect of 
the first two research questions (growth strategies adopted by Aspen and the 
challenges it faced).  Analytic generalisation was then used to answer the third 
research question and determine whether these propositions could be applied to 
other companies, where similar relationships, concepts and sequences might be 
relevant. 
 
1.8 Chapter Overview 
 
Chapter 1 Introduction and Overview 
 
This chapter introduces the research and sets out the framework of the study.   
 
Chapter 2 Literature Review 
 
This chapter provides the academic context in which the case study of Aspen took 
place.  A review of the relevant literature was intended to serve as the theoretical 
foundation on which to base the study.   
 
The theory on the core themes underlying the study of Aspen, namely strategy, 
the global pharmaceutical industry and business growth was considered.  These 
topics were explored in order to develop a framework for answering the research 
questions. 
 
Chapter 3 Research Design and Methodology 
 
This chapter builds on the theoretical foundation in Chapter 2 and sets out how the 
case study was conducted.  The research design and methodology adopted in this 





The research process followed, as well as the research design, is described.  This 
includes an explanation of the concepts of case study research, the sources of 
data (primary vs secondary) as well as the nature of data (quantitative vs 
qualitative).  The data collection method and data analysis process are also 
explained. 
 
Chapter 4 Case Study Analysis of Aspen 
 
This chapter sets out the results of the case study analysis of Aspen based on the 
conceptual framework set out in Chapter 3. 
 
The data extracted from the Aspen documents, with a focus on growth, is 
presented in the form of identified company milestones, as well as selected 
acquisitions and divestments which took place between 2004 and 2014.  Using 
key words, the growth of Aspen is then tracked and grouped according to years.  
From these key words, specific growth themes are identified and depicted.  Using 
specific indicators, the growth achieved by Aspen in numbers, is depicted in the 
form of graphs. 
 
A similar process is followed in respect of the challenges faced by Aspen – 
extracted key words are grouped according to years and from this arrangement, 
“challenge themes” are identified and depicted. 
 
Chapter 5 Discussion of Research Results 
 
Using the theoretical framework provided in Chapter 2, this chapter provides an 
examination and discussion of the research results from the case study contained 







The data is analysed and discussed in relation to each of the research questions 
in order to determine the growth strategies adopted by Aspen as well as the 
challenges faced by it in implementing such strategies.  Following from this, 
consideration is given to the learnings which other companies can take from these 
findings. 
 
Chapter 6 Conclusion and Recommendations 
 
This chapter concludes the study by setting out the implications of the research 
and summarising the conclusion to each of the research questions.  Based on the 
findings of the research, a model for sustainable growth is developed and 
illustrated.  The study closes by identifying the limitations of the research and the 




This chapter introduces the study and presents an overview of the research 
conducted.  A brief introduction to Aspen, as the subject of the case study 
analysis, is provided.  The problem statement is presented together with the 
research questions which the study seeks to answer.  Thereafter, the aim of the 
study, the motivation for the study, as well as the significance of the research is 
explained.  The research design and methodology utilised in order to answer the 
research questions is described and an overview of the remaining chapters to 
come is presented. 
 
The next chapter provides a review of the literature in order to develop a 






2.1 Introduction  
 
This chapter identifies and highlights the academic context in which the case study 
of Aspen took place and is intended to serve as the theoretical foundation on 
which the current investigation can be based.  The topics were explored in relation 
to the case study of Aspen as a means of developing a framework for addressing 
the problem statement and answering the research questions of this study. 
   
The purpose of this literature review was to consider the theory on the core 
themes underlying the study of Aspen, namely strategy, the global pharmaceutical 
industry and business growth.  This chapter therefore provides a consideration of 
the literature on what strategy is and some of the key concepts in strategy, 
specifically: the role of leadership in strategy, strategic leadership, core 
competencies, competitive advantage and strategic fit.   
 
The literature review also describes the global pharmaceutical industry, including 
the nature and dynamics of the industry.  This was intended to provide the context 
in which Aspen does business and illustrate the key driving forces shaping the 
competitive environment.  Against this background, some of the growth strategies 
adopted by global pharmaceutical companies were considered – these include 
organic growth, vertical integration, takeovers, mergers and acquisitions and 
internationalisation, with a focus on emerging markets. 
 
This chapter therefore sets out the framework used to examine the growth 










2.2 What is strategy? 
 
“Strategy means making clear-cut choices about how to compete.” 
Jack Welch, Former CEO, General Electric 
(Welch and Welch, 2005) 
 
In its most simplistic form, a company’s strategy is the plan by management on 
how it will run the business and conduct its operations.  The formulation of strategy 
signifies management’s decision and commitment to engage in a particular set of 
actions in order to grow a business, obtain and retain customers, conduct day-to-
day operations, compete successfully in the marketplace, and in so doing, improve 
the performance and financial position of the company (Hough et al., 2011). 
 
Michael Porter, considered to be one of the most prominent authorities on strategy 
(Magretta, 2011), claims that the core of strategy lies in activities – either by a 
company deciding to perform its activities differently or opting to carry out activities 
which are different to those of its rivals (Porter, 1996; Tanwar, 2013).  The former 
includes competing on price and being more efficient than rivals (shrinking the 
pie), whilst the latter requires the creation of a position based on a unique 
advantage (expanding the pie) (Ovans, 2015). 
 
The vast authors of subsequent strategy ideas propose that strategy does not 
come down to a choice between Porter’s two options.  Instead they suggest 
alternative approaches to strategy.  One of these is the concept that strategy is 
about doing something new (Ovans, 2015).  In the now-classic work “Blue Ocean 
Strategy,” the authors focus on finding or creating uncontested new markets which 
have not yet been identified by competitors.  In such market spaces, so-called blue 
oceans, competition does not exist and demand is generated rather than fought 
over (Kim and Mauborgne, 2015).  The authors contend that one of the prominent 
features of the blue ocean strategy is that, contrary to conventional theory on 
strategy, there is no need for companies to choose between value and cost.  
Creating a blue ocean allows a company to pursue differentiation and low cost 
simultaneously, and move away from the tendency of corporate strategy to focus 
on winning against competitors (red oceans) (Kim and Mauborgne, 2015). 
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Another alternative to Porter’s two options is the strategy of a company building on 
what it already does well (Ovans, 2015).  This is a focus on investing in 
strategically valuable resources (physical assets, intangible assets or capabilities) 
which provide a company with a competitive edge by enabling it to perform 
activities better or more cost effectively than rivals (Collins and Montgomery, 
2008). 
 
Finally, reacting opportunistically to emerging possibilities represents the most 
recent thinking in the strategy field (Ovans, 2015).  One of the themes in this area 
emphasises the importance of companies moving away from the traditional 
strategic planning model, which tends to be focused on specific business units and 
calendar driven, towards continuous decision-focused strategic planning (Mankins 
and Steele, 2006; Schermerhorn Jr., 2011).  The thinking is that this allows for 
companies to reach quality decisions through the continuous identification and 
systematic resolution of strategic issues – continuous strategy development 
(Mankins and Steele, 2006; Schermerhorn Jr., 2011).   
 
An alternative approach to opportunistic reaction as a strategy is a methodology 
called “lean start-up” which advocates the principles of continuous learning, failing 
early in a process, and searching for a business model which can be repeated and 
is scalable (Blank, 2013).  Given that established companies have to deal with the 
realities of frequent disruption and the need to continually innovate, it is thought 
that the same methods used by start-up companies should be implemented by 
other organisations to deal with ever-increasing external threats and allow for rapid 
innovation.  This includes acting rapidly, working in agile development teams and 
focusing on customer development to develop a business model which works, as 
opposed to the more traditional approach of measured speed with functional 
teams focusing on product management to develop a business plan (Blank, 2013). 
 
Finally, an approach which links the strategy of reacting opportunistically to 
emerging possibilities, argues that the theory and practice of strategy needs to 
keep up with the realities of today’s markets which are characterised as being 
virtually free of boundaries and barriers (Kinni, 2014).  The approach challenges 
Porter’s views on sustainable competitive advantage in today’s competitive 
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environment which is in perpetual motion.  It is said that in an environment of 
temporary advantage, competitive advantage must be thought of as something 
transient and companies should be organised in such a way as to exploit these 
temporary competitive advantages.  This requires thinking about strategy in a 
holistic way and possessing the ability to reorganise the people within a company, 
as well as its assets and capabilities, in such a way that the company can easily 
move from one opportunity to the next as the advantage changes (Kinni, 2014).   
 
Despite the criticisms of Porter, his work still contains many useful strategy 
theories and principles which can be applied in today’s modern business 
environment.  One of these is that competitive strategy is about being different, 
which requires an organisation to deliberately select a set of activities which 
distinguishes it from other organisations and enables it to deliver a unique value 
proposition.  This means that strategy is about creating a distinguishing and 
valued position, which involves performing a distinctive array of activities (Porter, 
1996; Harrison and St. John, 2014). 
 
Another useful principle from Porter is that strategy also lies in choosing what not 
to do.  This means that in selecting a strategic position, a company must identify 
which activities are incompatible and purposefully limit what the company offers, 
what Porter refers to as making trade-offs (Porter, 1996; Hunter, 2014). 
 
Such positioning choices are important not only in terms of a company choosing 
which activities it will perform but also the way in which it will organise such 
activities and how the activities will be arranged in relation to each another (Porter, 
1996; Harrison and St. John, 2014).  Porter goes to great lengths to emphasise 
that operational effectiveness is not strategy and what the difference is between 
the two.   
 
Operational effectiveness is achieved when activities or functions are performed in 
an optimal or superior way, whilst strategy is about how activities are combined 
and linked (Porter, 1996; Clegg et al., 2011).  In particular, a company with a good 
strategy ensures that its activities complement each other in order to create real 
financial benefits such as substantially reducing costs or increasing differentiation.  
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An example of this is when the cost of one activity is reduced because of the way 
in which the system of activities is performed.  This approach ensures that a 
strategic fit between activities is created which can give rise to competitive 
advantage and superior profitability.  Porter (1996) therefore contends that 
strategy is about establishing fit between the activities of a company.  The success 
of a strategy is thus dependent on many activities being performed well (not just a 
few) and integrating such activities – competitive advantage develops from the 
complete system of activities and a distinctive strategy is the result of the fit 
between the activities (Porter, 1996; Hunter, 2014). 
 
Essentially, the strategy of a company is about the “how” – how the business will 
achieve growth, how a customer base will be built, how the business will compete, 
how each functional part of the business will operate and so on (Hough et al., 
2011).  Having considered just a few ideas on what strategy is from the broad 
body of work on the subject – the richness, variety and complexity of these ideas 
suggest that Porter’s view that strategy boils down to a limited choice between two 
options may not be the only alternatives available to a company in crafting its 
strategy.  Instead, companies have the freedom to choose the “hows” of their 
strategy by selecting from a broad expanse of opportunity in order to become a 
productive and profitable enterprise (Ovans, 2015).   
 
2.3 Key concepts in strategy  
 
“The best way to predict your future is to create it.” 
Peter F. Drucker 
Widely known as the founder of modern management 
 
2.3.1 The role of leadership in strategy 
 
Much has been written on the definition and concept of leadership, which is often a 
central and sometimes controversial topic in organisational research (O’Reilly et 
al., 2010).  As research has confirmed that group and organisational behaviour is 
influenced by the behaviour of the leader (O’Reilly et al., 2010), it can be argued 
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that a company’s superior performance does not occur by chance but is largely 
shaped by the choices made by its leaders (Lear, 2012). 
 
As the role of leadership is seen to be fundamental to the success of an 
organisation (Lear, 2012) certain authors have adopted the view that leadership is 
in fact the true starting point of strategy and that, as strategy will not succeed in a 
vacuum, leadership is the key to identifying and realising great opportunities 
(Hsieh and Yik, 2005).  Leadership is therefore seen as being vital to the formation 
and implementation of strategy.  Other authors refer to leadership as being at the 
core of strategy, suggesting that the ability to formulate and implement strategy is 
one of the most important roles and a critical competence of a leader (Edinger, 
2013). 
 
This view may be said to be supported by Porter (1996) who sees the challenge of 
developing a clear strategy as being dependent on leadership.  He contends that 
powerful leaders, who are willing to take important decisions in terms of the 
choices they make, are required to maintain the company’s distinctiveness.  This 
requires that constant discipline is maintained to decide on the setting of limits, 
including which customers and needs the company should serve and which 
industry changes the company will respond to (Porter, 1996; Hunter, 2014). 
 
Strategy formulation and strategy implementation are said to be two of the most 
important elements in the strategic management process (Jooste and Fourie, 
2009).  Leadership, in particular strategic leadership, has broadly been identified 
as one of the main elements in the effective implementation of strategy (Pearce 
and Robinson 2007).  Correspondingly, the absence of leadership, and in 
particular strategic leadership, by the senior executives and management team of 
a company, is considered to be one of the main impediments to effective strategy 
implementation (Hrebiniak, 2005). 
 





2.3.2 Strategic leadership  
 
In the field of strategic management there has been an increased focus over the 
past 30 years on managers at the most senior levels and the impact which they 
have on the formulation and implementation of strategy, as well as on 
organisational performance (Waldman, Javidan and Varella, 2004).  As a result, 
more attention has been given in recent years to the concept and significance of 
strategic leadership (Lear, 2012). 
 
Strategic leadership, like most forms of leadership, has many different descriptions 
however it can best be defined as the ability to think strategically, anticipate 
events, visualise situations, maintain flexibility, as well as to work with others to 
introduce decisions which support the financial health of the organisation in the 
short term and lead to its survival and growth in the long term (Ireland and Hitt, 
2005; Rowe and Nejad, 2009). 
 
A clear vision and shared values are said to be the most important aspects of 
strategic leadership, as this empowers employees in the organisation to make 
independent informed decisions allowing the leader to have the time and capacity 
to focus on the high level issues affecting the company as a whole.  Such an 
environment, created under strategic leadership, is said to lead to continual growth 
and expansion of the company, resulting in a strong financial position being 
achieved and maintained (Rowe and Nejad, 2009; Edinger, 2013). 
 
Strategic leadership is differentiated from managerial or transactional leadership 
as well as the visionary or transformational leadership style.  Managerial 
leadership involves being predominantly involved in the activities of an 
organisation on a daily basis, and does not include a long-term vision for change 
and growth (Rowe and Nejad, 2009; Clegg et al., 2011).  On the other end of the 
continuum, visionary leaders are predominantly proactive, risk-taking and future-
oriented (Rowe and Nejad, 2009; Clegg et al., 2011).  Ideally, a strategic leader is 
one who is able to combine the positive elements of managerial and visionary 
leadership, thus being able to simultaneously take advantage of the positive 
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rational and risk-taking elements of these approaches (Rowe and Nejad, 2009; 
Cutler, 2014). 
 
Strategic leadership should not be seen to be within the exclusive domain of the 
chief executive of a company.  Given the vast amount of knowledge and expertise 
needed to understand and operate in many global markets, members of the top 
management team (comprising between three to ten of the company’s executives) 
through a team effort utilising their collective intellect and skills, should provide 
strategic leadership to the company and its large number of stakeholders (Ireland 
and Hitt, 2005; Clegg et al., 2011).  The examination of strategic leadership 
therefore does not concentrate not solely on the head of the organisation but also 
considers the executives who have general responsibility for such organisation 
(Lear, 2012).  Organisations make important choices about the strategies which 
they will adopt in order to achieve and enhance their competitive advantage and 
these decisions are made through their strategic leadership. 
 
Today’s global economy, characterised by unstable market conditions, a range of 
technological advances, complex competitive landscapes and a diversity of 
competitors, requires that the top management teams of organisations effectively 
exercise strategic leadership in the carrying out of their roles (Ireland and Hitt, 
2005; Clegg et al., 2011).  It is said that strategic leadership and its processes can, 
in themselves, be seen as a core competence in an organisation.  This is 
particularly the case when such leadership and processes are not easily 
understood by competitors and are thus difficult to replicate, thereby creating a 
competitive advantage for the company (Ireland and Hitt, 2005; Hill and Jones, 
2013). 
 
The meaning of core competencies is explained in the next section.   
 
2.3.3 Core competence 
 
Simply put, a company’s core competence is something which it does particularly 
well especially in comparison to its competitors.   Core competencies may be in 
the form of resources or capabilities, and they provide a competitive advantage for 
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a company over its rivals (Hitt, Ireland and Hoskisson, 2015).  Such core 
competencies allow a company to perform efficiently and effectively, which results 
in above average organisational performance (Clardy, 2007). 
 
Hough et al. (2011) distinguish a competence from a core competence in terms of 
a company’s proficiency to perform its operations.  Whilst a competence is 
something which a company does well, usually as a result of experience, a core 
competence is an expertly performed activity which plays a part in the strategy of a 
company and contributes to its success – it is therefore competitively important 
(Hough et al., 2011).  Thus, whilst a company may perform a number of 
competencies better relative to its competitors, not all of these competencies are 
“core” – core competencies are those which provide a company with a superior 
advantage (Agha, Alrubaiee and Jamhour, 2012). 
 
The authors C.K. Prahalad and Gary Hamel introduced the concept of core 
competence to management literature in 1990 (Hindle, 2008).  The authors 
identified core competencies as the way in which work is organised and value is 
delivered by an organisation.  The collective learning in an organisation (such as 
the way in which different production skills and multiple flows of technologies are 
coordinated) was also identified by the authors as a core competence (Prahalad 
and Hamel, 1990; Hitt, Ireland and Hoskisson, 2015). 
 
Some of the key elements of core competencies include the following: 
 
 they involve all functions and many levels of people in an organisation.  
Core competencies therefore require communication, involvement and 
commitment across organisational boundaries; 
 
 they are not diminished by use and should be supported and protected as 
their value is enhanced when shared and applied; and 
 
 they unite existing businesses and stimulate new business development. 
 
(Prahalad and Hamel, 1990) 
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The authors Prahalad and Hamel depict a diversified organisation as a large tree 
with the roots being the core competence which provide sustenance and stability 
(Prahalad and Hamel, 1990, cited in Hindle, 2008, p. 41).  These so-called roots of 
competitiveness must be identified and nurtured to make organisational growth 
possible.  Similarly, when looking at competitors, one should not only consider 
their end products (what the authors describe as the leaves on the tree) as one 
may not fully identify their strengths until the roots of their competitiveness are 
determined (Prahalad and Hamel, 1990; Clegg et al., 2011). 
 
The success of a company is not guaranteed merely because it possesses core 
competencies.  It is important that an organisation systematically identifies its core 
competencies and, in addition, develops and deploys them in the right way in 
order to leverage them to create a competitive advantage which is sustainable 
(Srivastava, 2005). 
 
The concept of competitive advantage is further explored in the next section. 
 
2.3.4 Competitive advantage 
 
Michael Porter’s book entitled Competitive Advantage, was published in 1985 and 
is said to have become “a bible of business thinkers” in the late 1980s (Hindle, 
2008, p. 37). 
 
In her book entitled “Understanding Michael Porter: The Essential Guide to 
Competition and Strategy,” Magretta (2011) argues that Porter’s powerful ideas 
have become business buzzwords and that many of the concepts are not properly 
understood.  The author sets out to present Porter’s concepts in a form which is 
easier to grasp.  As an example, the author suggests that the concept of 
competitive advantage is often used to mean anything which a company thinks it is 
“good at” when in fact competitive advantage is about creating unique value for 




Whereas Porter’s previous work Competitive Strategy considered competition at 
an industry level, with a company’s identity largely being described in relation to 
other companies (for example in terms of its relative size or market share), 
Competitive Advantage assumed a “company’s-eye view” of competition, with a 
greater focus on internal analysis by a company (Hindle, 2008).  From this unique 
perspective, the company is considered in terms of the series of activities which it 
performs and which link together to create customer value, forming what is called 
a value chain (Hill and Jones, 2013).   
 
In producing or delivering products or services, a company performs various 
activities which create value for buyers.  These activities combine to form what is 
known as the value chain and each link in the chain is an element which a 
consumer is willing to pay for, thereby adding value.  The two main categories of 
activities in a value chain are the primary and support activities.  The former are 
those which are the prime value creators whilst the latter are those which enable 
or enhance the primary activities (Hough et al., 2011).  These value chain activities 
form the basic units of competitive advantage, all of which combined should be 
managed and performed in such a way as to create a sustainable competitive 
advantage for a company (Porter, 1996; Clegg et al., 2011). 
 
As a company does not operate in isolation, it is also important to consider that its 
value chain exists within a broader arrangement of activities which includes its 
suppliers’ and distributors’ value chains (Hough et al., 2011).  As a result, a 
company’s delivery of a core competence to the market, or its cost 
competitiveness, are dependent on the effective management of its own value 
chain as well as on accurately assessing and managing those elements of the 
industry’s value chain system which impact on the company (Hough et al., 2011).   
 
Whilst a competitive advantage may be gained from a core competence and 
performing value chain activities efficiently, Porter (1996) views competitive 
advantage as the sum of all these parts.  A sustainable competitive advantage 




 creating a competitive position which is unique to the company; 
 
 ensuring that all activities of the company are aligned with its strategy; 
 
 making choices in relation to competitors, which may include trade-offs; 
 
 creating and strengthening a “fit”, integration and reinforcement among a 
company’s activities; 
 
 ensuring that a company’s strategy comes from the whole system of 
activities, not  its parts or individual activities; 
 
 developing operational effectiveness as a standard managerial 
responsibility and not as a strategy in itself. 
 
(Porter, 1996; Hunter, 2014) 
 
As mentioned above, a company’s external environment also has a bearing on a 
company’s strategy and this will be considered in more detail in the next section. 
 
2.3.5 Strategic fit 
 
The success of a company’s strategy depends on how compatible it is with the 
internal and external environment (Grant, 2013).  This concept of strategy being 
the link between a company and both its internal and external environment is 
known as strategic fit or alignment (Hunter, 2014).  The greater degree to which a 
company can create a fit between its structure and its environment, the more its 
performance will be improved (Gammeltoft, Filatotchev and Hobdari, 2012).   
 
In addition, to successfully operate in a business environment which is competitive 
and constantly changing requires that companies attain “fitness”.  This means that 
companies need to be able to learn from new circumstances and change to fit 
them as may be required (Beer et al., 2005).  Managing this strategic fit over time 
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is therefore an important ongoing and dynamic managerial capability (Gammeltoft, 
Filatotchev and Hobdari, 2012).   
 
Attaining superior organisational performance through the proper alignment of a 
company’s internal design variables and its environment’s external context 
variables (Gammeltoft, Filatotchev and Hobdari, 2012), requires an understanding 
of the framework within which the concept of strategic fit exists.  
 
As depicted in Figure 2.1 the framework consists of three parts: the inner section 
being the company itself, the middle section being the industry or 

























Figure 2.1 The components of a company’s environment 
 
Adapted from Hough, J., Thompson Jr, A.A., Strickland III, A.J. and Gamble, J.E. 
(2011) Crafting and Executing Strategy. 2nd ed.  Berkshire: McGraw-Hill 
Education, pp 57 and Grant, R.M. (2010) Contemporary strategy analysis.  7th 



















 Systems and 
structures 
 Capabilities and 
resources 




















The company itself embodies three elements, namely systems and structures 
(which relates to the functioning of the company and effective strategy 
implementation), capabilities and resources (these are the company’s competitive 
capabilities and resource strengths which set it apart from its competitors), and 
values and goals (which relate to a company’s vision on where it is going and the 
consistent, long-term goals it has to get there) (Grant, 2013). 
 
The industry or microenviroment analysis revolves around the determinants of the 
degree of profit in the industry.  An essential part of a successful strategy is a 
thorough understanding of this competitive environment, and three factors may be 
identified to determine the profits earned by the companies in a particular industry.  
These are the following: 
 
(i) Competitors: the intensity and level of competition within the industry; 
 
(ii) Suppliers: the economic power of suppliers or bargaining power of the 
company in relation to its suppliers; 
 
(iii) Customers: the value of the product to the company’s customers as well as 
the bargaining power of the company relative to such customers. 
 
(Grant, 2013; Harrison and St. John, 2014) 
 
The macroenvironment consists of the external elements within which all 
companies operate, rather than a particular industry, such as a country or region.  
Of relevance is how these factors, which are more general in nature, affect a 
company’s industry as a whole and the company itself (Hill and Jones, 2012).  
Thus a company will be concerned with the macroeconomic factors which are 
relevant in terms of having an influence on its industry and the business decisions 
which it makes (Hough et al., 2011).  The different factors can have varying 
degrees of impact on organisations, may occur with or without warning, and may 
occur rapidly or slowly.  Organisations must therefore remain constantly aware of 
these factors, assess the impact which they may have and the decisions which will 
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need to be made to deal with them, including potential changes of direction and 
strategy (Hough et al., 2011). 
 
For multinational companies, achieving strategic fit takes on additional complexity 
and becomes a multidimensional challenge (Gammeltoft, Filatotchev and Hobdari, 
























Figure 2.2 Dimensions of strategic fit for multinational companies 
 
Adapted from Gammeltoft, P., Filatotchev, I. and Hobdari, B. (2012) Emerging 
multinational companies and strategic fit: A contingency framework and 
future research agenda, European Management Journal 30 (3), pp. 175 – 188, 
pp 177. 
 
For a multinational company, strategic fit and alignment must be attained in 
multiple institutional settings and along a number of dimensions, both domestically 
and in the wider global environment (Gammeltoft, Filatotchev and Hobdari, 2012).  
As a result, multinational organisations need to align across companies (between 
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(home country, host country and the global environment), and at multiple levels 
(Gammeltoft, Filatotchev and Hobdari, 2012).  This is in addition to the traditional 
aspects of strategic fit between the organisation and its internal and external 
environment, which were previously discussed. 
 
2.4 The nature and dynamics of the global pharmaceutical industry 
 
The global pharmaceutical industry is a large, established and complex industry, 
with a number of stakeholders including governments, pharmaceutical companies 
(both innovator and generic producers), healthcare insurance providers, 
physicians, pharmacists and patients/consumers (Appelt, 2010).  The industry is 
expected to grow to nearly US$1,3 trillion in total global spending by 2018 – an 
increase of US$290 – 320 billion from 2013 (IMS Institute for Healthcare 
Informatics, 2014), as depicted in Figure 2.3.  This growth is driven by population 
growth, an ageing population, generic drugs, as well as market expansion and 
improved access in so-called “pharmerging” markets (IMS Institute for Healthcare 



































Figure 2.3 Global pharmaceutical market spending and growth, 2008 – 2018 
 
Adapted from IMS Institute for Healthcare Informatics (2014) Global Outlook for 
Medicines Through 2018, November [Online].  Available at: 
http://static.correofarmaceutico.com/docs/2014/12/01/informe_ims.pdf, pp. 5. 
 
Pharmerging markets are developing countries where the use of pharmaceuticals 
is growing rapidly and total drug spending over the next few years is expected to 
see the fastest growth, particularly in respect of lower-cost generics (Lorenzetti, 
2015).  The category is defined as countries that are expected to see more than 
US$1 billion in absolute spending growth from 2014 to 2018, and which currently 
have a gross domestic product per capita of less than US$25,000 – the biggest 
being China, followed by Brazil, India and Russia; followed by smaller emerging 
markets such as Mexico, Turkey, Venezuela, Poland and thirteen others (a total of 
21) (Lorenzetti, 2015). 
   
Pharmaceutical companies expend large amounts of sunk research and 
development costs in order to discover a new drug and bring it to the market 
(Brekke, Koenigbauer and Straume, 2006).   In order to ensure that such costs are 
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not a deterrent and to stimulate innovation, pharmaceutical companies with new 
innovations are protected by intellectual property rights, namely patents, which 
provide them with market power in the form of a monopoly by restricting competing 
companies from copying the innovation during a certain period (usually 20 years) 
(Brekke, Holmas and Straume, 2011).  Effectively this market exclusivity allows for 
such innovator or brand-name drugs to be sold at high prices (due to the fact that 
there is no competition driving prices down), allowing for the research and 
development costs to be recouped. 
 
When the patent expires, competing companies may enter the market with generic 
versions of the innovator drugs (Brekke, Holmas and Straume, 2011).  A generic 
drug is bioequivalent (identical) to a brand-name drug in dosage form, safety, 
strength, route of administration, quality, performance characteristics and intended 
use – this therapeutic equivalence must be proved before the product can be 
launched on the market (U.S. Food and Drug Administration, 2015).  Whilst 
generic drugs are chemically identical to the equivalent branded drug, they are 
usually sold at much lower prices than the branded product.  The reason for this is 
that the generic pharmaceutical company is able to manufacture the drug without 
expending the research and development costs which the innovator company had 
to incur (U.S. Food and Drug Administration, 2015).  
 
Another type of medication is known as biologicals.  Whilst conventional drugs are 
made of pure chemical substances, biological products are made from living 
organisms.  The material which they are made from can come from a number of 
different sources including animals, microorganisms (such as yeast or bacteria), 
as well as humans (U.S. Food and Drug Administration, 2015).  Biosimilars are a 
type of biological product which are substantially similar to an already approved 
biological, however they cannot be said to be “generics” of biologicals as they are 
not identical due to the fact that they are made from living organisms and therefore 
have allowable differences (U.S. Food and Drug Administration, 2015).  Thus 
whilst biosimilars compete with biologicals by aiming to mimic them at a lower 
price, due to the complex nature of biologicals, they are much more difficult to 
identify and thus replicate.  This often allows biological products to maintain 
market dominance even after their patents have expired (Ward, 2015). 
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A distinction should also be drawn between prescription and over-the-counter 
(OTC) pharmaceuticals.  The former are prescribed by a doctor and can be bought 
at a pharmacy whilst the latter can be bought off the shelf, without a prescription, 
from a variety of stockists (U.S. Food and Drug Administration, 2015).  In this 
regard, the pharmaceutical industry is different to many other industries where the 
consumer chooses and pays for the good.  In the prescription market, the choice 
of which drug is consumed by a patient is largely made by the treating physician 
and, in many countries, pharmacists can and may be mandated to substitute a 
generic equivalent of a branded drug.  In addition, for many consumers, the costs 
of prescription drugs are also shared with insurance or medical plans.  The co-
payment which such plan may charge a member may also influence the choice of 
drug (Guha, Lacy and Woodhouse, 2008).   
 
The pharmaceutical industry is characterised by a complex and evolving 
regulatory landscape.  Legislation forms the basis of pharmaceutical regulation 
(Deloitte, 2014).  Aside from the regulatory control to support innovation in the 
form of patents, discussed above, there are two further aspects to this regulatory 
control.  The one is aimed at protecting consumers’ health and safety (quality 
regulations) and the other is aimed at containing costs (price regulations).   
 
The first aspect is the pharmaceutical approval process which is highly regulated 
and means that product commercialisation can only take place after compliance 
with all required product standards, which can take many years (Deloitte, 2014).  
Pharmaceutical companies must incur large costs and fees, resulting in reduced 
returns on investment, in order to comply with stringent safety and quality 
standards (Milmo, 2014). 
 
The second aspect is pricing control, which takes place in most countries (both 
developed and emerging markets).  This involves regulators seeking to reduce the 
cost of pharmaceuticals through pricing and reimbursement legislation (Aspen, 
2014).  Governments, healthcare providers and health insurance plans seek to 
reduce drug spending costs by instituting price controls and increasingly endorsing 
the use of generics and biosimilars (Deloitte, 2014).  
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The highly regulated nature of the pharmaceutical industry is just one of the 
barriers to entry which are said to make the industry difficult to enter.  A barrier to 
entry is any advantage which established companies have over entrants (Hill and 
Jones, 2013).  Other pharmaceutical industry barriers to entry include: 
 
 High capital requirements: a capital intensive industry, such as 
pharmaceuticals, is one which requires a substantial amount of capital for 
the production of goods.  Pharmaceutical companies must expend huge 
amounts of capital costs to develop or acquire products as well as to 
establish the production facilities to manufacture the products (Burns, 
Bradley and Weiner, 2012).  The costs of a new company establishing itself 
in this market may therefore be prohibitive. 
 
 Significant economies of scale: the capital and technology intensive nature 
of the pharmaceutical industry means that efficiency requires a large-scale 
operation.  Established companies build significant manufacturing 
capabilities to attain large-scale production in order to reduce unit costs and 
increase profit margins.  Such technology and manufacturing capabilities 
are therefore an important source of competitive advantage (Burns, Bradley 
and Weiner, 2012). 
 
 Access to or control over supply and distribution channels: established 
companies often create a large operational network supporting their 
business.  An efficient and effective distribution network is essential and 
can give rise to a competitive advantage.  In addition, control over the 
supply channel, such as access to low-cost sources of raw materials, can 
provide established companies with a unit cost advantage over new 
entrants (Grant, 2013). 
 
In a study of the 10 pharmaceutical companies which, based on total shareholder 
return, consistently outperformed the industry over a 20 year period, certain 
recurring factors were found (Bain & Company, 2014).  Firstly, they all 
concentrated on building a leadership position in specific capabilities and 
categories.  Secondly they all used targeted merger and acquisition (“M&A”) 
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strategies to build on their leadership positions (Bain & Company, 2014).  Most of 
the focused M&A strategies resulted in deals which were aimed at delivering 
sustained value and which built speciality category leadership positions (thus 
linking to the first mentioned factor).  To illustrate this, between 1992 and 2012, 
eight of the studied core pharma companies generated 70% of their cumulative 
revenue inorganically and the bulk of this (80%) came through M&A (Bain & 
Company, 2014). 
 
The study acknowledged that the enduringly successful pharmaceutical 
companies had to make difficult choices about where and where not to focus their 
investments and efforts.  This pointed to the significance of strong business 
leaders with a clear vision of the importance of leading in pharmaceutical 
categories (category leadership) and distinctive business capabilities (capability 
leadership) which allowed for survival and superior value creation in the constantly 
changing pharmaceutical industry (Bain & Company, 2014). 
 
The pharmaceutical industry has been described as unique as it continues to be 
profitable despite the changing and challenging business environment in which it 
operates (Laws, 2015).  The industry is also, by its nature, a defensive sector due 
to the fact that people continue to need pharmaceuticals regardless of the 
economic environment (particularly chronic medication), which can translate into 
fairly stable cash flows for pharmaceutical companies (Cairns, 2011). 
 
According to IMS Institute for Healthcare Informatics (2014), the pharmaceutical 
industry is expected to be driven by high levels of growth during the next five 
years, in comparison to the past five years.  Some of the reasons for this include 
the following: 
 
 expected strengthening of the global economy; 
 
 increased pharmaceutical spending in pharmerging countries as a result of 
government-funded economic stimulus programmes and increased access 
to new medicines and healthcare; 
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 demographic trends including an ageing population in developed markets, 
population growth in emerging markets, as well as an increase in the 
diagnosis and treatment of chronic and lifestyle diseases. 
 
(IMS Institute for Healthcare Informatics, 2014) 
 
Some of the distinguishing features of this growth in the pharmaceutical industry 
include the following: 
 
 globally generics are the biggest growth driver, with Latin America being the 
largest contributor and North America the smallest contributor; 
 
 rising demand in Latin America will be focused on locally manufactured 
generics.  In African markets, local manufacturers often receive preferential 
treatment in order to encourage domestic production, as these locally 
manufactured products are the main source of affordable drugs in these 
markets; 
 
 growth in pharmerging markets is likely to be driven mainly by generic and 
non-branded products which are expected to double the growth rate of 
branded products; 
 
 in developed regions (such as Europe and North America) speciality 
medicines are bigger drivers of spending growth than in pharmerging 
markets.  In Europe, speciality medicines have become a key growth driver 
as the majority of new drugs are aimed at catering to the unmet needs of 
specific niche populations. 
 
(IMS Institute for Healthcare Informatics, 2014; Hillmann and Bates, 2015; 




Such growth will however not be without its difficulties.  In an industry 
characterised by intense global competition, increasing government and payor 
pressure to reduce costs and demonstrate value, restrictive legislation, and 
slowing growth in developed markets, pharmaceutical companies will need to 
focus their commercial efforts on containing costs, maintaining regulatory 
compliance and increasing focus on emerging markets (Deloitte, 2014). 
 
2.5 The growth strategies of a global pharmaceutical company 
 
2.5.1 The growth imperative 
 
In business it is said that growth is an imperative not an option and some authors 
even go to the extent of saying “your company can either grow or die” (Rich, 1999, 
p. 27).  Growth is key to long term success as it is a prerequisite for increasing 
revenue, profits and shareholder value.  A business that is growing is a healthy 
business as it ensures that the business has a future and is an attractive prospect 
for investors (Strategic Direction, 2006; Bürkner, King and Razali, 2013). 
 
A survey of over 1,200 chief executives from many of the world’s largest and most 
complex companies revealed that growth is an imperative and a focus in the 
broader business strategies (KPMG, 2015).  In particular, in the top strategic 
priorities and challenges facing CEOs, growth was a factor in every single one 
(KPMG, 2015).  This emphasis on growth has gained focus amongst the 
leadership structures of many prominent companies who have introduced a new 
role in senior management known as the Chief Growth Officer (CGO) (Dalton and 
Dalton, 2006).  The role is aimed at ensuring that sustained and profitable growth 
remains at the forefront of a company’s strategy (Buss, 2014). 
 
There are a number of diverse approaches to growing a company.  Growth 
through internally focused organic growth, externally focused inorganic growth, or 
a combination of both, is available to most companies, regardless of their size.  
Each has its benefits, risks and trade-offs and careful planning and execution is 
required to ensure that the end result creates value for the company (Kuntz, 
2014).  A carefully formulated growth strategy, appropriate to the company and 
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which takes into account the importance of execution and integration, is key to 
achieving sustainable growth. 
 
In the global pharmaceutical industry, faced with pricing and cost pressures, 
stringent regulations and shrinking margins in both mature and emerging markets, 
growth is fundamental to continued survival and profitability (Roland Berger, 
2013).  The next section will focus on some of the growth strategies available to 
global pharmaceutical companies. 
 
2.5.2 Organic growth 
 
Organic growth is the growth rate achieved by a company due to internal 
operations, which excludes any growth or profit from takeovers, mergers or 
acquisitions.  Organic growth is achieved when a company grows from within and 
is also known as core growth as it is the growth from the core of the company 
(Dalton and Dalton, 2006).  Organic growth is said to be a useful sign of how 
effectively the management of a company has used internal resources to generate 
profits (Investopedia, 2015). 
 
Mognetti (2002, p. xviii) describes organic growth as a permanent opportunity 
which is a “stone’s throw” away from where a company is currently positioned.  
Organic growth is said to offer a less expensive, faster and less risky short-term 
return on investment than external growth (Mognetti, 2002). 
 
A basic form of organic growth involves selling more of a company’s existing 
products to its existing customers and is also known as market penetration 
(Duckler, 2015).  The focus is on leveraging a company’s resources and 
capabilities to optimise existing customer relationships.  Two of the ways in which 
this can be achieved is through an improvement in marketing effectiveness (such 
as increasing advertising) or sales productivity (such as increasing the sales 
force).  Whilst not overly innovative, these efforts can lead to broad scale and 




2.5.3 Vertical integration 
 
Vertical integration occurs when two businesses, which are at different stages of a 
value chain, merge.  This may be contrasted to horizontal integration which occurs 
when two businesses at the same stage of production or a value chain, merge 
(Hindle, 2008).  Vertical integration is thus a company’s ownership of activities 
which are vertically related.  This may take the form of either backward integration, 
where the company takes ownership and control of an activity behind it such as 
the production of its own components or inputs, or it can be forward integration, 
where the company takes control of an activity further on in the production process 
such as activities undertaken by its distributors (Hill and Jones, 2013). 
 
The more parts of the stages of the value chain which a company owns in respect 
of its products, the greater the degree of vertical integration.  In this regard vertical 
integration may also be full (where the company owns the whole value chain) or 
partial (where the company uses a combination of its own value chain as well as 
others – producing and selling its products using both company businesses as well 
as outside sources) (Hitt, Ireland and Hoskisson, 2015).   
 
One of the major benefits of backward vertical integration is the control which it 
gives a company over its access to the inputs which it requires – including the 
cost, quality and delivery of such inputs (Hindle, 2008).  The conventional 
determinant of vertical integration is to compare the efficiency of markets with the 
efficiency of firms, thus if the cost of transacting through the market at a particular 
stage of the value chain is greater than the cost of administering the activity within 
the company then vertical integration should take place for the benefit of the 
company (Grant, 2013). 
 
In the generic pharmaceutical industry there is often a distinct separation between 
the upstream and downstream parts of the supply chain.  Upstream manufacturers 
produce active pharmaceutical ingredients (“APIs") (which are chemical 
compounds with therapeutic properties) through the use of raw materials such as 
catalysts, solvents and chemicals.  These APIs are supplied to downstream 
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manufacturers who combine them with inactive ingredients and process them into 
finished products such as tablets (Kubo, 2011). 
 
The sourcing of APIs is an important part of generic product development (Kubo, 
2011).  As a result, backward vertical integration by a generic drug manufacturer 
into API manufacturing provides critical mass and a number of advantages.  These 
include greater control of the supply chain, the ability to ensure timely availability 
of the required API to allow uninterrupted production of the generic products, and 
input cost reduction resulting in greater profit margins – all of which contribute to 
the growth of the generic company. 
 
2.5.4 Takeovers, mergers and acquisitions 
 
Takeovers, mergers and acquisitions involve the growth of a company other than 
from its own business activities and are therefore forms of inorganic growth.  Such 
inorganic growth is considered to be an accelerated form of growth as it generally 
results in new skills and knowledge being available, gives rise to an increase in 
assets and market share, and provides access to capital and new markets faster 
than by means of organic growth (Kuntz, 2014).  Mergers and acquisitions in 
particular are considered to be important tools in corporate strategy as they allow 
companies to achieve major expansions in the range of their activities and thus 
accelerate the company’s growth (Gaughan, 2013). 
 
Whilst takeovers and acquisitions have a similar meaning, an acquisition could 
relate to either a company or a product.  A takeover however generally refers to 
one company acquiring another company and in so doing taking on the target 
company’s operations, assets and liabilities.  A takeover may have a negative 
connotation particularly in the context of a hostile takeover.  This occurs when the 
takeover is accomplished without the acquiring company coming to an agreement 
with the target company’s management.  Instead the acquiring company 
purchases shares directly from the shareholders of the target company in order to 
secure a controlling interest (Investopedia, 2015). 
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A merger takes place when two companies join and form a new company.  This 
requires the consent of the shareholders of both companies.  Mergers typically 
occur when the two companies are of comparable strength and size and an 
entirely new company is formed (Gaughan, 2013).   
 
Whilst mergers and acquisitions (“M&As”) are not new to the global 
pharmaceutical industry, the current dealmaking activity which is taking place has 
been described as “a frenetic explosion of M&A activity” (Wieczner, 2015), “merger 
fever” (Megget, 2015), and “a record wave of dealmaking” (Ward, 2015).  
According to a PwC report on deals in the pharmaceutical industry, in the first half 
of 2015 the total global closed deal value in the pharmaceutical sector was 
approximately US$170 billion, nearly double the total closed deal value for the 
whole of 2014 (PwC, 2015). 
 
From an analysis of the multitude of deals, involving both horizontal and vertical 
activity, a number of trends have been identified: 
 
 Consolidation: the trend of consolidating business units or companies into a 
larger organisation is often associated with M&As as it is a means of 
gaining larger market share and creating shareholder value (KPMG, 2015).  
It is also intended to create and explore synergies, achieve critical mass 
and improve operational efficiency aimed at long-term cost optimisation and 
savings. 
 
 Divestitures: whereas in the past, pharmaceutical dealmaking was largely 
focused on achieving sheer scale and building a broad portfolio of products 
for a range of illnesses (The Economist, 2014), there is now an increasing 
move towards divesting low margin and non-core products and operations.  
Coupled with the acquisition of specific products and businesses, there is 
thus a move to build leadership in specific categories and capabilities, and 




 Generic companies: traditional generic companies have been shifting their 
strategic focus and restructuring their product portfolios in order to gain 
access to niche and specialised products and create a diversified product 
portfolio (KPMG, 2015).  This allows them to capitalise on more 
opportunities, such as gaining access to new technologies and capabilities 
(Harding, 2010). 
 
In an industry searching for innovation and growth in an environment of 
contracting prices and profit margins, M&As offer pharmaceutical companies the 
opportunity to effectively purchase growth “off-the-shelf” (Ward, 2015).  Rising 
demand and competition for generic drugs, as well as loss of revenue from 
blockbuster patent expiries is driving both generics and research-based 
companies to look for acquisitions of varying sizes in order to consolidate and 
achieve economies of scale (Deloitte, 2014).   
 
Providing access to new products and new markets is an attractive prospect for an 
acquiring company, however using M&As to expand involves a number of major 
risks (Gaughan, 2013).  The current so-called “M&A frenzy” of competition for 
valuable assets has prompted bidding wars which has resulted in valuations 
ballooning and companies paying an acquisition premium to obtain the targeted 
company or product (Megget, 2015).  In addition to being expensive, the purchase 
may include a large amount of additional capabilities and resources which are not 
required by the acquiring company (Grant, 2013).  Finally, integration of the 
capabilities/company into the acquiring company is often a major challenge which 
requires a significant investment of effort, time and other resources (Schroeder, 
2013).  Proper selection and integration of company acquisitions thus requires 
comprehensive planning and understanding (Christensen et al., 2011). 
 
2.5.5 Internationalisation and the focus on emerging markets 
 
In the pursuit of growth, new customers and profitability, internationalisation 
presents a multitude of markets and offers vast opportunities to companies.  At the 
same time, such expansion is complex and requires thorough research and 
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planning as well as a strategic approach before the company’s resources are 
committed to new markets (Lessard, Lucea and Vives, 2012). 
 
The move from a national to an international trading environment requires a focus 
on the profit implications of such expansion.  The profitability of entering a foreign 
market rests on two key factors: (i) the attractiveness of the market, and (ii) 
whether the company can create a competitive advantage in such market, 
particularly in relation to local companies and other multinationals.  This latter 
requirement depends on whether the company is able to move or replicate its 
capabilities and resources to the new market whilst still retaining the ability to 
generate a competitive advantage (Grant, 2013). 
 
Assuming these two requirements are met and the company determines that the 
potential exists for it to create value from internationalisation, this is only the start 
of the journey.  Thereafter, the company needs to design the international strategy 
as well as the suitable organisational structures and systems to support it (Cullen 
and Parboteeah, 2014). 
 
2.5.5.1 Modes of market entry 
 
Entry into a foreign market takes place through trade or contractual modes (being 
the sale and delivery of products or services from one county to another) or direct 
investment (which involves acquiring or building assets in another country which 
can produce the goods or services) (Reinert, 2012).  Between each of these 
approaches is a range of market entry options. 
 
According to Grant (2010) the spectrum of options for market entry can be 
arranged based on the level of resources committed by the company, as depicted 


























Figure 2.4 Alternative modes of foreign market entry 
 
Adapted from Grant, R.M. (2010) Contemporary strategy analysis. 7th ed.  
United Kingdom: John Wiley & Sons Ltd, pp. 383. 
 
At the far left extreme, exporting takes place through individual transactions and 
requires low resource commitment by the company, relative to the far right 
extreme which involves the establishment of a wholly owned subsidiary, requiring 
a high level of resource commitment by the company (Grant, 2010; Reinert, 2012). 
 
The following key factors may be used to guide a company’s decision regarding 
which mode of entry to select: 
 
1. Is the company’s competitive advantage country-specific or is it based on 
company-specific assets or resources?  
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2. Can the product be traded and, if so, are there any barriers to such trade? 
3. Does the company hold all of the capabilities and resources which are 
required to create a competitive advantage in the foreign market or will 
additional resources need to be obtained in-market? 
4. Can returns be directly allocated to the company’s resources? 




2.5.5.2 Structures and systems 
 
A critical element in the strategy design and implementation process is the choice 
of organisational structure and arrangement of management systems.  In 
particular, it is important that these structures and systems align with the company 
and its pursued strategies (Worren, 2013).  Getting these building blocks right can 
be a critical determinant of competitive advantage, whilst failing to do so can 
severely constrain the company’s strategic capabilities. 
 
Three basic strategy-structure configurations can guide companies in designing 
their organisational structure, as depicted in Figure 2.5. 
 
                
 
 
Figure 2.5 Parent-subsidiary structure options 
 
Adapted from de Wit, B. and Meyer, R. (2010) Strategy: Process, Content, 









The shading indicates the concentration of decision making, thus moving from the 
left of the figure: (i) in decentralised federations, each subsidiary is able to operate 
independently and undertakes all of the company functions; (ii) in coordinated 
federations the parent retains a dominant position in terms of capital, new 
products, management capabilities and systems, whilst the overseas subsidiaries 
are given substantial autonomy; and (iii) in centralised hubs, global strategies and 
production are controlled from the parent company whilst the subsidiaries are 
responsible for activities such as sales and distribution (de Wit and Meyer, 2010). 
 
Whilst these strategy structures provide basic frameworks, a convergence of these 
strategies, which represents a less static form and aims to maximise the benefits 
and minimise the drawbacks of each of these approaches, has developed into 
what is known as the transnational organisation.  The transnational organisational 
structure combines the capabilities of the independent subsidiaries upon which the 
company’s international business is built (decentralised federations), with the 
control, coordination and integration of these operations at a central level 
(centralised hubs) (Bartlett, 1986). 
 
As depicted in Figure 2.6, the transnational organisation is an integrated network. 
 
                            
 
Figure 2.6 The transnational organisation 
 
Adapted from de Wit, B. and Meyer, R. (2010) Strategy: Process, Content, 
Context.  4th ed.  United Kingdom: Cengage Learning EMEA, pp. 546. 
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The transnational organisation thus represents a network of dispersed capabilities 
and resources which are integrated and interdependent.  This allows the 
organisation to adapt to the different needs and requirements in respect of 
products and functions, in the various countries (Grant, 2013).  This structure 
therefore recognises the need for a company to be simultaneously globally 
efficient and competitive, on the one hand, and responsive to national differences, 




A global strategy is one which regards the world largely as a single market with 
little local variation (Lynch, 2014).  Whilst there are certain benefits to having a 
global strategy, the need for national differentiation should not be overlooked.  
Glocalisation (a combination of the words globalisation and localisation) is the 
incorporation of local aspects into products which are sold globally.  It involves 
balancing the efficiencies of operating on a global scale with the need for local 
adaption, and recognises that there is a greater likelihood of succeeding in 
transplanting a product into a new market if it is adapted to meet local preferences 
(Matusitz, 2010).   
 
Companies should standardise their activities and the features of their products 
where economies of scale demand this.  At the same time, they should allow for 
differentiation where country specific preferences are greatest – thus requiring a 
careful combination of global standardisation and local adaptation (Grant, 2013). 
 
2.5.5.4 Pharmerging markets 
 
Whilst the pharmaceutical industry continues to grow in developed markets, the 
level of future growth is uncertain and expected to flatten.  This is due to the 
changing healthcare reforms which result in pricing pressures, as well as 
macroeconomic factors (IMS Institute for Healthcare Informatics, 2014).  Emerging 
pharmaceutical markets, so called “pharmerging markets”, are however expected 
to grow more strongly than developed markets and are thus considered to offer 
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significant growth opportunities for pharmaceutical companies (McKinsey & 
Company, 2012). 
 
It is expected that by 2016, these rapidly growing emerging markets will amount to 
almost one third of the global pharmaceutical market (approximately double the 
percentage in 2006) and are therefore seen to play a vital role in sustaining growth 
in the pharmaceutical industry (PwC, 2013).  Some of the key growth drivers 
include large populations, an increase in wealth and income levels, a growing 
trend towards healthier lifestyles, as well as increasing government and consumer 
awareness about the benefits of a good healthcare system (Deloitte, 2014). 
 
Accessing this untapped potential is however not without its difficulties as 
pharmaceutical companies, who attempt to establish or increase their presence in 
these expanding markets, find they that are faced with a number of risks and 
challenges, including: 
 
 increasing government intervention through mechanisms such as price 
setting and changes in manufacturing requirements; 
 increased competition as local and multinational companies enter these 
markets; 
 geographic size and cultural diversity; 
 underdeveloped healthcare infrastructure and fragmented distribution 
systems; and 
 the growth markets differ on a number of levels including their geographies, 
politics, religions, as well as socially and structurally.  They also differ in 
respect of the medications which they require and their ability and 
willingness to pay for new medicines. 
 
(McKinsey & Company, 2012; PwC, 2012) 
 
Given the commercial potential which these markets hold, both generic and 
innovator companies are responding to the opportunities which these new, 
expanding markets offer, either on their own or by pursuing mergers, acquisitions 
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or joint ventures.  However given the diversity among these regions, a “one-size-
fits-all” approach cannot be used (PwC, 2013).  Commercial success is thus likely 
to be dependent on a thorough understanding of each market and its intricacies, 
investment in local research, development and manufacturing as well as tailoring 
commercial models and approaches to meet the specific needs and characteristics 
of each market (Deloitte, 2014).  This need for localisation thus requires that 
pharmaceutical companies balance their global competencies with tailored 
approaches for the local markets (PwC, 2013). 
 
2.6 Summary  
 
The purpose of this literature review was to consider the theory on the core 
themes underlying the case study analysis of Aspen, namely strategy, the global 
pharmaceutical industry and business growth. 
 
In essence, a company’s strategy is the plan by management on how it will run the 
business and conduct its operations (Hough et al., 2011).  Whilst Porter (1996) 
claims that the essence of strategy is in a company deciding either to perform its 
activities differently or opting to carry out activities which are different to those of 
its rivals, the vast authors of subsequent strategy ideas propose that strategy does 
not come down to a choice between these two options.  Instead, it is suggested 
that companies have the freedom to choose the “hows” of their strategy by 
selecting from a broad expanse of opportunity to become a productive and 
profitable enterprise (Porter, 1996; Ovans, 2015). 
 
Against the above background, some of the key concepts of strategy were 
considered.  These included an emphasis on the importance of leadership in 
strategy and the concept and significance of strategic leadership.  Theory 
regarding core competencies, competitive advantage and strategic fit were also 





An analysis of the nature and dynamics of the global pharmaceutical industry was 
aimed at illustrating the large, complex and unique nature of the competitive 
environment in which Aspen operates.  This analysis provided the context for 
considering certain of the growth strategies adopted by global pharmaceutical 
companies.  This involved a consideration of the imperative for growth as well as 
the concepts of organic growth, vertical integration, takeovers, mergers and 
acquisitions and internationalisation, particularly in emerging markets. 
 
In order to address the research questions to be answered in this study, a 
descriptive case study analysis was conducted on Aspen.  Chapter 3 covers the 








The last chapter provided the academic context in which the case study of Aspen 
took place.  This chapter builds on this theoretical foundation and sets out how the 
case study was conducted. 
 
This chapter therefore sets out the research design and methodology adopted in 
this study.  The purpose of this chapter is to conduct a literature review of how to 
perform research and sets out the choice and justification of the particular 
research method adopted. 
 
The chapter commences with a theoretical explanation of the concept of research, 
which includes an overview of the research process.  This is followed by a 
description of the choice of research and the research design.  The research 
design covers the concepts of case study research, the sources of data (primary 
vs secondary) as well as the nature of data (quantitative vs qualitative).  Finally, 
the data collection method and data analysis are explained. 
 
3.2 The concept of research 
 
According to Bourgeois (2011), human beings have an innate desire and need to 
explain the world around them.  As a result of this, disciplined study is used to give 
meaning and purpose to life and its processes.  The purpose of research is 
therefore to learn about how the world works as this understanding is said to 
provide the ability to predict or control events (Bourgeois, 2011). 
 
Extending this social-scientific approach to the business context, Cooper and 
Schindler (2014) describe research as an organised enquiry which is carried out to 
provide information for solving problems.  More specifically, business research is a 
methodical investigation which provides information aimed at guiding decision 
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makers in order to mobilise the organisation to take actions which maximise its 
performance (Cooper and Schindler, 2014). 
 
The research process is the method of designing and conducting research, from 
the formulation of ideas about a research topic to the final reporting of the results 




Figure 3.1 The research process 
 
Adapted from Dul, J. and Hak, T. (2008) Case Study Methodology in Business 
Research, Burlington, Massachusetts: Elsevier Ltd, pp. 13. 
 
Whilst the research process is depicted as a sequential process involving clearly 
defined steps, certain of the steps may take place out of sequence and even 
simultaneously and each step need not be completed before going to the next.  
However, for the purposes of developing the research project and keeping it 
orderly it is useful to show the process as a sequence (Zikmund et al., 2013). 
 
 
Select the research topic 
Determine the research objective and type of research 
Plan the research design 
Gather the data 
Analyse the data 
Report the research 
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The decision on the type of research is linked to the objectives of the study.  
Essentially, a study will either be causal, descriptive or exploratory in nature 
(Sekaran and Bougie, 2013).  A causal study is one which is aimed at determining 
and explaining the relationship between variables (Cooper and Schindler, 2014).  
A descriptive study is one which provides an overall “picture” of a population or 
phenomenon by describing a situation or events (Thyer, 2001).  Finally, an 
exploratory study is conducted when little is known about an event or situation and 
the research aims to discover and generate theory (Sekaran and Bougie, 2013).   
  
The research design is the plan of a study and the way in which the research 
questions will be answered.  It is the framework for the study which outlines the 
type of data which will be collected, the sources of the data, how the data will be 
measured and ultimately the analysis of the data (Cooper and Schindler, 2014). 
 
3.3 Choice of research 
 
The choice of the type of research is determined by the kind of research question 
which the study is trying to answer.  The purpose of this research was to identify 
and analyse the growth strategies adopted by Aspen over the past 11 years (2004 
– 2014). 
 
The nature of this research was thus concerned with finding out “what” as opposed 
to “why”.  The question being asked is therefore “what has happened” contrasted 
with “why did something happen” (Yin, 2012).  As a result the research is of a 
descriptive nature, as opposed to explanatory in nature, and for this reason a 
descriptive study was selected as the type of research. 
 
In addition, a descriptive study was considered the appropriate research approach 
due to the fact that (i) the elements (growth strategies) were not yet known and 
were to be discovered in the research, and (ii) the identification and description of 
these elements did not involve the testing of causal relations between variables 




The aim of a descriptive study, as the name suggests, is to describe.  Studies of 
this nature are thus usually constructed to accumulate data which describes 
people, organisations, occurrences or situations and their characteristics (Sekaran 
and Bougie, 2013).  As a result, the information is collected without any 
manipulation and the research may therefore be referred to as an observational 
study. 
 
3.4 Research design 
 
The research method used was a descriptive study through a single case study of 
Aspen by analysing secondary data in the form of publicly available company 
reports and presentations, as well as financial results, issued by Aspen between 
2004 and 2014.  Qualitative data was extracted and analysed to determine the 
growth strategies used by Aspen, whilst certain quantitative data was used for 
illustrative purposes.   
 
The nature of and rationale for pursuing a descriptive study were explained above.  
The rest of the elements of the research design will now be individually analysed. 
 
3.4.1 Case study research 
 
Yin (2012) defines a case study as an enquiry about a phenomenon in its real-
world setting.  The “case” is the phenomenon which is being studied and a case 
study is usually conducted on one or a few cases.  This is one of the features of a 
case study as the in-depth analysis of the case/s allows an invaluable and 
insightful understanding to be gained, with the aim of producing new knowledge 
about behaviours and their meaning (Yin, 2012).  The fact that the case is studied 
in its real life context is another distinctive characteristic of the case study as 
neither the phenomenon nor its environment are manipulated (Dul and Hak, 2008). 
  
A case study is considered to be appropriate for use in a descriptive study when 
answering a research question such as “what is happening or has happened?” as 
a case study is able to provide the detailed descriptions or explanations required 
to answer a question of this nature (Yin, 2012; Farquhar, 2012).  This can be 
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contrasted with the experiment (which may be useful when trying to determine the 
effectiveness of an initiative) and the survey (which may be used to determine how 
often something has happened) (Yin, 2012). 
 
Furthermore, a case study is appropriate for understanding an event in its actual 
setting as the method used is often a collection of data in natural settings over 
which the researcher has no control (Remenyi, 2013).  This is different to relying 
on data which is derived from responses – such as in an experiment (where a 
researcher uses various instruments to obtain responses) or a survey (where a 
researcher uses a questionnaire to obtain responses) (Sauro, 2015).  
 
For these reasons, a descriptive case study was considered to be the appropriate 
method for identifying and analysing Aspen’s growth strategies over the past 11 
years (2004 – 2014). 
 
Although case studies may be used to study many real-world situations and can 
address important research questions, it is often criticised as a research method 
and has not received general recognition as the method of choice (Yin, 2012).  
Some of the reasons for this include: 
 
 a case study is not considered to involve a serious enquiry and lacks rigour; 
 
 the credibility of the case study is questioned due to the potential for bias by 
the researcher in finding what they set out to find, that is it lacks objectivity; 
and 
 
 that it is not possible to generalise the results of the case study for wider 
use, that is it lacks generalizability. 
 





Yin (2012) argues that these criticisms are outdated and whilst the potential for 
such challenges exist, the effective contemporary approach to case study 
research employs systematic procedures to overcome these potential pitfalls.  
Through systematic data collection and examination, the researcher may use 
analytic generalisation to allow the case study findings to be generalised to other 
situations (Yin, 2012). 
 
It is therefore the responsibility of the researcher to ensure that the methodology 
employed overcomes these challenges and upholds the reliability of the case 
study research. 
 
The type of case study design selected was a holistic single case study, meaning 
a single-unit of analysis and single-case was used (as opposed to multiple units 
and multiple cases), namely Aspen.  Whilst such a method may be criticised for 
being too narrow, this approach was selected as it allows for the selected case to 
be analysed in detail and allows the researcher to study the phenomenon more 
intensively.  Having become the largest pharmaceutical company (i) in Africa, and 
(ii) listed on the Johannesburg Stock Exchange (South African stock exchange) 
(Aspen, 2014) Aspen was considered a unique and rich enough source of 
information to warrant individual analysis. 
 
A case study allows for an emphasis on detail in order to provide valuable insights 
and places more focus on a full contextual analysis (Cooper and Schindler, 2014).  
Using qualitative analysis in respect of a single or small number of occurrences, 
conclusions are usually arrived at (Dul and Hak, 2008).  This can be contrasted to 
a statistical study which is designed for breadth rather than depth as the 
characteristics of a population (with a large number of instances) are presented by 
making inferences from a sample.  In a statistical study, hypotheses are generally 







3.4.2 Sources of data: primary vs secondary  
 
Cooper and Schindler (2014) define data as the facts which are provided to a 
researcher from the setting of a study.  There are two sources of data, namely 
primary data and secondary data.  Primary data is information which is collected 
first hand by a researcher, specifically for the purpose of their study, through tools 
such as interviews and surveys.  Secondary data is information which already 
exists such as company records and archives.  The nature of secondary data is 
that it was collected by someone other than the researcher for another purpose 
and was not originally collected for the researcher’s specific study (Lee, Lee and 
Lee, 2013). 
 
For this study, data was obtained by accessing the company reports, 
presentations and financial results issued by Aspen between 2004 and 2014 and 
made publicly available on the company’s website.  This is therefore secondary 
data. 
 
One of the advantages of using secondary data is the breadth of the data which is 
available.  An individual researcher may not have the resources to personally 
collect and collate the information which is made available through the secondary 
data.  This links to another advantage of using secondary data which is economy, 
in that the researcher does not have to expend the resources (time, cost and 
experience) in collecting the data “from scratch”.  Another advantage is that often 
the secondary data has been obtained through an expert and professional process 
which may not be available to an individual researcher (Boslaugh, 2007). 
 
There are however certain inherent disadvantages to using secondary data as 
opposed to primary data.  One of these is that the researcher has no control over 
how the data was collected.  As the data was not collected for the specific purpose 
of answering the researcher’s particular study objectives, there may be excessive 
data which the researcher has to review but which is not relevant to the topic.  
Conversely, information which the researcher requires may not have been 
collected.  In addition, having no participation in the planning and execution of the 
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data collection process, the researcher may not know exactly how it was carried 
out and therefore what the validity of the data is (Boslaugh, 2007). 
 
The reliability of secondary data in the form of archival data may also be affected 
by the bias of its preparers (Yin, 2012).  For example the selection of data used 
and how events are portrayed, may be subject to systematic bias.  A researcher 
using archival data should therefore be sensitive to the editorial choices made by 
the preparer of the data, and guard against simply accepting the data as factual 
without remaining aware of potential shortcomings in the data (Yin, 2012) 
 
In this study, Aspen’s Annual Reports, presentations and financial results, which 
are made publicly available on its website, were utilised as the source of 
secondary data.  Aspen is a public company which means that it is permitted to 
offer shares to the public.  As a result, it is listed on the Johannesburg Stock 
Exchange (“JSE”).  The main function of the JSE is to provide a facility for 
securities to be listed and at the same time to regulate the marketplace for the 
orderly trading of such securities (JSE, 2014). 
 
As part of this regulation, the JSE has issued Listings Requirements which apply 
to companies when listing for the first time on the JSE, as well as to those 
companies which are already listed.  The JSE Listings Requirements contain rules 
and procedures and are “aimed at ensuring that the business of the JSE is carried 
on with due regard to the public interest” (JSE, 2014, p. 3).  The General 
Principles in the JSE Listings Requirements must be followed in all corporate 
actions, in particular there is an obligation on listed entities to: 
 
(v) “ensure that all parties involved in the dissemination of information into 
the market place, whether directly to holders of relevant securities or to 
the public, observe the highest standards of care in doing so;” and 
 
(vii) “ensure that the Listings Requirements, and in particular the continuing 
obligations, promote investor confidence in standards of disclosure and 
corporate governance in the conduct of applicant issuers’ affairs and in 
the market as a whole.” 
 
(JSE, 2014, p. 4) 
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In light of the above, there is an obligation on listed entities, such as Aspen, to 
ensure that the information which they disseminate into the marketplace, including 
its Annual Reports, presentations and financial results, meets the highest standard 
of care.  This requirement lends credibility to such documents. 
 
In terms of the JSE Listing Requirements, listed entities are required to issue an 
Annual Report which includes the company’s annual financial statements.  An 
Annual Report is a publication which a listed company issues after each financial 
year which essentially chronicles the activities of the company over the past year.  
The Annual Report also contains details regarding the operational and financial 
condition of the company and its performance over the preceding financial year 
(Investopedia, 2015). 
 
The Annual Reports are issued to the public as they are intended to provide 
valuable information to existing and prospective shareholders (who are the 
ultimate owners of the company) on the company’s performance and positioning.  
This includes items such as the company’s objectives and performance 
(particularly financial) during the period under review, as well as the strategy and 
future direction of the company (Ernst & Young, 2008). 
 
The performance highlights in an Annual Report provide key financial and 
statistical information on the company’s performance during the period, which can 
be compared to the company’s past performance as well as measured against the 
objectives and strategies of the company.  These can be used to determine how 
financially sound the company is, how well it is being managed and what progress 
it is making in achieving its goals (Ernst & Young, 2008). 
 
Listed companies also provide information regarding their strategies in the Annual 
Reports as this gives shareholders an understanding of the decisions made in 
respect of the allocation of the company’s resources.  Information regarding a 
company’s organisational capabilities as well as the key risks and challenges it 
faces in achieving its purpose, are critical for investors to determine the strategic 
positioning and competitive advantage of the company (Ernst & Young, 2008).  In 
addition to the explicit information provided regarding a company’s strategy, the 
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financial results provide an indication of the success of a strategy in terms of 
output, outcome or impact (PwC, 2015). 
 
Over the past two decades, the field of corporate reporting has evolved and grown 
in importance.  An increased focus on sustainability and the so-called “triple 
bottom line” of people, planet and profit as well as the advent of the King Reports 
on Corporate Governance for South Africa and the International Integrated 
Reporting Framework have brought Annual Reports (now referred to as Integrated 
Reports) to the fore as one of the most prominent channels of a company’s 
communication with its stakeholders (PwC, 2014).   
 
As one of the primary purposes of an Annual Report is accountability to 
stakeholders, particularly shareholders, listed companies are expected to move 
beyond the traditional financial focus of solely business thinking and reporting, 
towards conveying information about the organisation’s strategy, performance and 
future prospects (PwC, 2014).  An organisation’s Annual Report is now expected 
to provide details of its strategy including how such strategy translates into its 
ability to generate value in the short, medium and long term.  The Annual Report 
should also indicate how the organisation is performing against such strategy.  An 
Annual Report is thus intended to provide invaluable insight into the organisation 
through management’s eyes (PwC, 2013).   
 
As a result, Aspen’s Annual Reports were considered to be a reliable source of 
information on the growth strategies adopted by the company and how successful 
such strategies had been in terms of translating into positive financial 
performance.  Such reliability was however tempered by an awareness of the 
potential shortcomings of secondary data as well as the potential bias in the 








3.4.3 Nature of data: quantitative vs qualitative 
 
“Not everything that can be counted counts, 
and not everything that counts can be counted.” 
Albert Einstein 
 
The basic distinction between quantitative data and qualitative data is that the 
former is in the form of numbers and the latter is in the form of words (Sekaran 
and Bougie, 2013).   
 
Cooper and Schindler (2014) define quantitative research as the attempt to 
precisely measure something, for example measuring consumer behaviour 
opinions, and this methodology is used to answer questions such as “how much”, 
“how often”, or “how many”.  This can be contrasted against qualitative research 
which aims to obtain a comprehensive understanding of a situation and thus seeks 
to describe the meaning, as opposed to the frequency, of a phenomenon (Cooper 
and Schindler, 2014). 
 
Quantitative data often consists of participant responses to research instruments 
such as surveys or questionnaires.  These need to be categorised and reduced to 
numbers so that they can be subjected to statistical analysis.  Such process can 
be distinguished from qualitative data where text in the form of detailed 
descriptions is obtained, analysed and interpreted by the researcher (Zikmund et 
al., 2013). 
  
Qualitative data is often criticised as being too subjective and susceptible to 
human bias in its collection and interpretation.  However, quantitative data is not 
without its limitations as it is said to lack the insights which qualitative data may 
provide and which is often critical to facilitate a business decision (Cooper and 
Schindler, 2014; Creswell, 2015).  The researcher remains responsible for taking 
steps to alleviate the shortcomings of the data and its analysis by carefully 
planning the research process and structuring the data analysis in such a way as 
to avoid the pitfalls.  
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This study was based on qualitative data.  This was considered to be the most 
appropriate approach given that the research utilises the descriptive case study 
method in answering questions about what growth strategies were adopted by 
Aspen and what challenges it faced in implementing such strategies.  Such 
questions required a comprehensive understanding (qualitative analysis) as 
opposed to measuring frequency (quantitative).   
 
Qualitative data was thus extracted from Aspen’s Annual Reports and 
presentations, and analysed to determine the answers to the research questions.  
In addition to this, certain quantitative data from the financial results was selected 
as this was considered useful for illustrative purposes and to give context to the 
qualitative data. 
 
3.5 Data collection and analysis 
 
Dul and Hak (2008) simplistically yet effectively define data collection as the 
process of selecting an object of measurement, extracting evidence of the 
characteristics from such an object, and recording such evidence. 
 
From Aspen’s publicly available corporate website, the following documents, 
issued by Aspen during the period 2004 to 2014 (both years inclusive), were 
downloaded and saved: 
 
 Annual / Integrated Reports; 
 interim financial results (December of each year), including results 
presentations, announcements and booklets; 
 final financial results (June of each year), including results presentations, 
announcements and booklets; and 
 presentations (such as investor and site presentations). 
 
The time period of 2004 to 2014 was selected as (i) Aspen has a 30 June financial 
year end and thus, at the time of the study, the most current data available was in 
respect of the 2014 financial year; (ii) working back from the 2014 data, an eleven 
year period in the company’s history was considered long enough to provide 
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valuable insight into the company, whilst at the same time being reasonable and 
manageable in terms of the researcher’s resource constraints. 
 
These documents, which totalled 58, were the source of the qualitative and 
quantitative data described in the previous section. 
 
Prior to collecting the data, it was important that the research questions to be 
answered at the end of the study were framed.  The questions served as a mental 
framework for collecting the data and ensured that such collection was focused 
and intentional.  The questions were as follows: 
 
1. What growth strategies has Aspen adopted over the past 11 years (2004 – 
2014)? 
2. What challenges has Aspen faced in implementing the growth strategies? 
3. What learnings can other companies take from the case study analysis of 
Aspen?  
 
Using the mental framework of the research questions, the accessed documents 
were read in their entirety, and carefully and comprehensively analysed to extract 
qualitative and quantitative data.  The accessed documents were read 
chronologically from oldest to most recent. 
 
With regard to the qualitative data, narratives and words were extracted from the 
accessed documents and systematically organised into a word table for each year.  
The tables were divided into multiple rows and two columns – the first column 
being the data copied and pasted from the accessed documents and the second 
column being key words to describe the data.  
 
Selection of the data for the first research question, relating to growth, was guided 
by identifying the following: 
 
 key words and themes such as “growth” and “strategy” as well as related 
words and themes; 
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 details regarding products (such as launches), transactions, acquisitions 
(products and businesses), divestments (products and businesses), 
expansion (of capacity and geographically), partnerships and joint ventures, 
and capital expenditure projects; 
 stated strategies; 
 initiatives and success factors; 
 core competencies;  
 strategic objectives and initiatives; and 
 company milestones. 
 
The data extracted from the documents was collated into one document resulting 
in an approximately 300 page document being produced.  The process of data 
reduction involved further editing this data to remove repetitive and superfluous 
information, reducing the document to 20 pages.  From this document the data 
was narrowed down to key words for each year under review and arranged into a 
data display which encouraged conclusion drawing through the establishment of 
meaningful themes or patterns.  Based on these key words, core themes were 
identified. 
 
The same approach was followed in respect of the extraction and organisation of 
the data for the second research question relating to challenges.  Selection of the 
data for this enquiry was guided by identifying the following: 
 
 the key word “challenge/s” and related words and themes; 
 stated challenges; and 
 business and operational risks. 
 
The data extracted from the documents was collated into one document resulting 
in an approximately 30 page document being produced.  The process of data 
reduction involved further editing this data to remove repetitive and superfluous 
information, reducing the document to approximately 14 pages.  From this 
document the data was narrowed down to key words for each year under review 
and arranged into a data display which was aimed at facilitating conclusion 
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drawing through the establishment of meaningful themes or patterns.  Based on 
these key words, core themes were identified. 
 
The quantitative data in the accessed documents was also analysed and selective 
information was extracted (data reduction) and exported into a spreadsheet (data 
display).  The spreadsheet was arranged in columns for each year and rows for 
each of the categories set out below: 
 
 revenue (money brought in by a company from goods sold); 
 operating profit (profit earned by a company from the core operations of the 
business); 
 earnings per share (measures the profitability per share); 
 headline earnings per share (earnings per share from core operations of the 
business); 
 market capitalisation at year-end (total market value of a company’s 
outstanding shares); 
 share price at year-end (market price of one share); 
 cash flow from capital expenditure – property, plant & equipment 
(acquisition or upgrade of physical assets); 
 cash flow from capital expenditure – intangible assets (acquisition of assets 
such as intellectual property rights); and 
 cash flow from the acquisition of subsidiaries and businesses. 
 
The quantitative data was also converted into graphs, with the intention of 
obtaining a better understanding of the data through this form of data display and 
possibly identifying a pattern which could facilitate the drawing of conclusions 
(Sekaran and Bougie, 2013).  For example a dramatic increase in profit in one 
year, encouraged a more focused look at the corresponding qualitative data for 
that year, to determine what events took place and investigate whether a causal 
relationship could be established between the increase in profit and the activities 
of or steps taken by the company in that particular year. 
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In quantitative studies, where a research instrument such as a survey or 
questionnaire is used, researchers often input their numeric data into a pre-
packaged computer software program which utilities an automated algorithm to 
produce output data for analysis.  Case study analysis is however less formulaic 
and, with no prescribed or routine procedure to follow, the researcher must 
determine what process they will use to logically extract data and then essentially 
create a unique “algorithm” to piece such data together into broader logical themes 
for interpretation (Yin, 2012). 
 
The qualitative data analysis was aimed at making valid inferences from the 
considerable amount of data which was collected (Sekaran and Bougie, 2013).  
The details extracted from the accessed documents represented raw data.  The 
purpose of the data analysis was to convert this into more useable information by 
reducing it into a manageable size through the process of data reduction (Cooper 
and Schindler, 2014). 
 
As the motive for doing the case study was to answer the research questions, the 
technique for analysing the data was directed at these questions.  The data was 
summarised and categorised which allowed for patterns and themes to be 
identified.  By organising both the qualitative and quantitative data chronologically, 
insightful descriptive patterns were produced (Farquhar, 2012).   
 
Attempting to answer the third research question, namely what learnings other 
companies can take from the case study analysis of Aspen, involved the process 
of generalisation.  Whilst quantitative research, in the form of surveys and 
questionnaires for example, usually involves statistical generalisations through 
generalising the known traits of a sample to the population from which they are 
drawn (sampling logic), case study research is more suited to analytic 
generalisation based on replication logic (Piekkari and Welch, 2011). 
 
This required that the first stage of the case study identified relationships, 
concepts and sequences of events which could assist with arriving at findings in 
respect of the first two research questions (growth strategies adopted by Aspen 
and the challenges it faced).  Determining whether these propositions could be 
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applied to other companies, where similar relationships, concepts and sequences 
might be relevant, was the second stage.   
 
Through analytic claims, the case study thus attempts to generalise the findings to 
other situations.  It should however be noted that such generalisations are not 
intended to be conclusive but instead provide a theoretical proposition which 





This chapter set out and explained the research design and methodology which 
was selected and utilised in this study with the intention of answering the stated 
research questions. 
 
Against a theoretical background defining research as disciplined study used to 
give meaning and purpose to life and its processes, the research process was 
described.  As the choice of the type of research adopted (exploratory, descriptive 
or causal) is linked to the objectives of the study, a descriptive study was 
considered the appropriate approach for this research. 
 
In order to identify and analyse the growth strategies adopted by Aspen over the 
past 11 years (2004 – 2014), a case study was selected as the appropriate 
method as this allowed for the company to be considered in detail as well as in its 
real-world context.  Criticisms of the case study approach were considered, 
emphasising the responsibility of the researcher to ensure that the research 
methodology overcomes such challenges.   
 
The differences between primary and secondary data were described and the 
reasons for using secondary data for this study were provided.  An explanation of 
the JSE Listings Requirements (which Aspen, as a listed entity, is subject to) as 
well as the growth in importance of corporate reporting, highlighted the value of 
the information which a listed company disseminates in communicating with its 
stakeholders. 
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Quantitative data (numbers) was utilised for illustrative purposes whilst qualitative 
data (words) was used to facilitate an in-depth comprehension of the subject 
matter.  The method of data collection and analysis were explained.  This included 
using the research questions as a framework to collect the raw data, through an 
analysis of Aspen’s publicly available Annual Reports, presentations and financial 
results (issued by the company).  Such data was then reduced and converted into 
more useable information through a process of chronological and systematic 
summarising to allow for meaningful patterns and themes to be identified, and 
thereafter analytic generalisation was used in an attempt to apply the findings to 
similar situations. 
 
Having described the research design and methodology adopted, the results of 




























This chapter sets out the results of the case study analysis of Aspen, based on the 
examination of secondary data in the form of Aspen’s publicly available Annual 
Reports, presentations and financial results.  These case study results are 
presented according to the conceptual framework set out in Chapter 3. 
 
A brief introduction to Aspen is provided followed by the stated strategic objectives 
contained in the Annual Reports between 2005 (the 2004 Report did not contain 
this information) and 2014, in relation to the goal of sustained growth.  The 
analysis of the Aspen documents, with a focus on growth, is presented in the form 
of the identified company milestones up to 2014, as well as selected acquisitions 
and divestments which took place between 2004 and 2014.  
 
The growth of Aspen is then tracked through key words which are grouped 
according to years.  From these key words, specific growth themes are identified 
and depicted.  Using specific indicators, the growth achieved by Aspen in 
numbers, is depicted in the form of graphs. 
 
The challenges faced by Aspen are then identified by the grouping of key words 
according to years.  From these key words, “challenge themes” are identified and 
depicted. 
 
4.2 Introduction to Aspen 
 
Aspen supplies branded and generic pharmaceutical products globally.  It also 





The Aspen Group’s strategic direction is determined by its vision (Aspen, 2014, p. 
4): 
ASPEN’S VISION 
“To deliver value to all stakeholders as a responsible corporate citizen that provides 
high quality, affordable medicines and products globally.” 
 
 






Figure 4.1 Aspen values 
 
Aspen (2013) Aspen Pharmacare Holdings Limited Integrated Report 2013, 




4.3 Stated strategic objectives 
 
As part of its corporate governance reporting, from 2005, Aspen set out in its 
Annual Reports the identified business and operational risks which it faced as well 
as the initiatives or success factors which contributed to the reduction of such risk.  
These provide useful insight into the strategic objectives of the business, 
particularly with regard to growth. 
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In 2005 the initiatives or success factors in mitigating the business and operational 
risk of “Maintenance of a leading position in the South African Market” were: 
 
 Increasing investment in new product development; 
 Pioneering the manufacture of generic ARVs in Africa; 
 Continually commercialising new pharmaceutical products; 
 Cost-effectively supplying the growing generic  pharmaceutical market; 
 Diversifying manufacturing capability into healthcare consumer products eg. 
infant milk formulas; 
 Organic expansion into new markets eg. Africa; and 
 Acquisitive growth. 
 
(Aspen, 2005, p. 54) 
 
In 2006 the identified business and operational risk was broadened to “Sustaining 
growth” and, in addition to the 2005 initiatives and success factors set out above, 
the following mitigating elements were identified: 
 
 Diversifying manufacturing capability; 
 Expansion into new markets; and 
 Differentiating Aspen from competitors through niche products and markets. 
 
(Aspen, 2006, p. 55) 
 
In 2007 the following additional initiatives and success factors were identified: 
 
 Diversifying and increasing manufacturing capability; 
 Assessing acquisitive opportunities; 
 Ability to source and launch new product pipeline; and 
 First to market in new product launches. 
 
(Aspen, 2007, p. 58) 
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In 2008, a number of new initiatives and success factors were identified: 
 
 Increasing awareness of Aspen’s brands in all markets; 
 Identifying, fostering and leveraging business relationships with credible, 
established partners; 
 Optimising strategic relationships with multi-nationals; 
 Upgrading and improving manufacturing facilities to ensure sustained 
compliance; 
 Transforming the organisation for international growth; and 
 Optimising on the experience, competence and expertise of capable people 
to drive future growth. 
 
(Aspen, 2008, p. 80) 
 
In 2009, these were expanded to include the following: 
 
 Expanding into new markets, with a particular emphasis on emerging 
markets; 
 Supplying cost-effective, high-quality products; 
 Sourcing and launching the new product pipeline; 
 Attracting and retaining appropriately experienced and skilled employees; 
 Upskilling employees to work with new technology, new markets and new 
products; 
 Consistent application of best practice throughout the Group; and 
 Growing leaders. 
 
(Aspen, 2009, p. 88) 
 
In 2010, the risk mitigation initiatives and activities were identified as: 
 
 Aspen has expanded into a broad base of international territories to 
diversify the Group’s growth opportunities; 
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 Aspen’s product pipeline extends across a number of key therapeutic 
categories for each region; 
 Significant investment has been made in the Group’s manufacturing 
facilities to secure supply of high quality products to meet future demand 
and manufacturing requirements; and 
 The product pipeline and manufacturing capability enables the Group to 
focus on a portfolio of specialised products for growing disease 
management regimes. 
 
(Aspen, 2010, p. 92) 
 
In 2011 the strategic risk of “Effective strategy and ability to ensure the long-term 
growth of the Aspen Group” was said to be mitigated by the following initiatives: 
 
 The Group Chief Executive and Deputy Group Chief Executive continuously 
monitor the relevance and sustainability of the Group strategy and update 
the Board at least quarterly; 
 Aspen has been effective in building and leveraging strategic relationships 
with leading pharmaceutical companies worldwide and the continuity and 
expansion of these relationships is managed by the Group Chief Executive, 
Deputy Group Chief Executive and Group executives; 
 Aspen’s flexible business model and quick decision-making ability enables 
it to respond with speed to growth opportunities which are presented to the 
Group; and 
 Executive management in each region is responsible for monitoring market 
indicators, for identifying regional growth opportunities and ensuring 
effective implementation of the approved strategy. 
 
(Aspen, 2011, p. 60) 
 
In 2012 the following mitigation activities were identified: 
 
 The Group’s strategy is reviewed and approved by the Board annually; 
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 The strategy provides for an entrepreneurial response to a dynamic 
operating environment; and 
 The Group’s strategy is translated into annual budget plans and the key 
performance indicators of the business are monitored quarterly. 
 
(Aspen, 2012, p. 81) 
 
In 2013 a separate Key Risk Mitigation Activities Report was made available 
online.  Aspen’s business model was set out, namely: 
 
ASPEN’S BUSINESS MODEL 
Aspen’s strength lies in its understanding of the dynamic markets in which the 
Group operates and identifying and pursuing opportunities that align with the 
Group’s vision and strategy.  The Aspen business model creates value for 
stakeholders by the application of high levels of expertise and advanced processes 
under the framework of the Group’s values to optimise the returns on its unique 
assets, tangible, intangible and human. 
 
(Aspen, 2013, p. 5) 
 
In expanding on the business model, the following key enablers were identified in 
the quest to deliver value to stakeholders: 
 
 Diverse, niche and innovative intellectual property that is relevant to the 
regions we operate in – acquired, developed and licensed; 
 Robust product pipeline for targeted strategic regions; 
 Significant presence in emerging markets; 
 Accredited strategic and regional manufacturing facilities that are flexible 
and scalable to demand.  In-house as well as third party manufacturing 
network; and 
 Committed employees living the Aspen values. 
 
(Aspen, 2013, p. 5) 
 
In the 2014 Annual Report, the challenges and risks which Aspen faced in relation 
to its strategic objectives were set out.  These strategic objectives, considered and 
agreed annually by the Board of Directors, included the following: 
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 To deliver sustainable growth in earnings from a diversified portfolio of 
products and geographies; 
 To supply customers and patients with high quality medicines at competitive 
prices; 
 To increase the direct promotion of Aspen products worldwide; 
 To achieve superior returns on investment for our shareholders over the 
long term; 
 To continuously increase and improve our offering to healthcare 
professionals and patients through a prolific product pipeline; 
 To achieve a strategic advantage through our production capabilities; and 
 To be alert to opportunities to enhance the value of the Group for its 
stakeholders. 
 
(Aspen, 2014, p. 4) 
 
This section has set out the following elements, relating to growth, drawn from the 
analysis of the Aspen documents: 
 
- stated strategic objectives,  
- initiatives and success factors; 
- risk mitigation initiatives and activities; 
- the company’s business model; and 
- challenges and risks in relation to the strategic objectives. 
 
These offer invaluable insight into the organisation through management’s eyes 
(PwC, 2013).  As a result they provided a foundation for the further analysis of the 
company in order to achieve the study objectives. 
 
4.4 Focus on growth  
 
Aspen is listed on the Johannesburg Stock Exchange (“JSE”) (the South African 
stock exchange), and has its Group headquarters in Durban, South Africa.  Aspen 
has grown from a company with businesses in South Africa, Australia and the 
United Kingdom and a market capitalisation of approximately R4,8 million in 2004, 
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to a truly global company with businesses on six continents and a market 
capitalisation of R136 billion in 2014 (Aspen, 2014). 
 
Aspen is now the largest pharmaceutical company listed on the JSE and is one of 
the top 20 companies listed on this stock exchange.  It is ranked among the top 
five generic pharmaceutical producers globally and has 26 manufacturing facilities 
at 18 sites on six continents and approximately 10 000 employees (Aspen, 2014). 
 
Against this background, the growth of Aspen was considered by tracking the 
developments reported in the Annual Reports between 2004 and 2014.  These 
company milestones are summarised in Appendix 1. 
 
In addition to the company milestones, a useful way of analysing the nature of the 
business and the changes thereto over the period 2004 to 2014, was by extracting 
selected acquisitions and divestments, as set out in Appendix 2. 
 
Drawing from this information and a comprehensive analysis of the Annual 
Reports issued by Aspen between 2004 and 2014, it was possible to extract key 
words relating to the growth strategies which Aspen adopted.  These are depicted 

























 strategic investment 
 
2005 















































increasing generic volumes 
new product launches 
investment  
specialist manufacturing 
product development capabilities 
access to new markets 
explore acquisitive prospects 
extended international footprint 
2007 
enhancement of manufacturing  
capacities 
standards 
strategic production capabilities 
competitive advantage 
organic growth  
strengthening product pipeline 
acquisitive opportunities 





acquisition (business, products) 
internationalisation 
 strength in emerging markets 
investment in capital expenditure 
 tangible fixed assets 
strategic decision to divest 
shifting focus to emerging markets 
organic growth 






































 regionally focused to global 
concentration on emerging markets 
South Africa business 
 catalyst to growth 
 investment in capital projects 
 product development 
intensive period of acquisitive activity 
 access to new markets 
critical mass 
rights to products 
strategic transactions 
organic growth 
 product pipeline 
period of significant investment 
business and product 
acquisitions 
property, plant and equipment 





enhancements to manufacturing 
capabilities 
 critical strategic asset 
strategic advantage 
disposals 
 no fit with business model 
key driver of organic growth 
 product pipeline 
acquisitive opportunities continue to be 
assessed 
capital investment programme 




product launch plan 
profit generation 
 primary objective 
diversified into international markets 
products selected in terms of the growth 
objectives and profitability    
  prospects in each territory 
implementing business model to 

































focus on core business 
 discontinuations 
 disposals 
expanding geographic presence 
organic growth 
 product pipeline 
valuable asset 
critical to sustainability 
significant investment in manufacturing 
 technologies 
 capacities 
globally competitive manufacturer 
material asset classes 
 goodwill 




 pharmaceutical business, products 
and manufacturing facilities 
carefully selected product portfolio for 
each territory 
organic growth 
 pre-existing products and business 
 product pipeline 
strategic commercial partnerships 
emerging pharmaceutical markets 
 high level of focus 
2012 
capital expenditure 
continued investment in 
manufacturing facilities 
 continued competitiveness 
 strategic advantage 
transformation from a predominantly SA  
business to a diversified global   
business 
seeking growth opportunities in other 
geographies 
 emerging pharmaceutical markets 
organic growth 
 product pipeline 
 differentiated products relevant to  
specific markets 
value enhancing acquisition 
 portfolio of products 























Figure 4.2 Tracking Aspen’s growth through key words in the 2004 – 2014 
Aspen Annual Reports 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
Identifying and analysing these key words was an essential element of this study.  
It provided insight into the activities and objectives of the company and its 
management during the period under review.  It was important to be able to 
identify what strategies were being implemented in each year, which strategies 
were abandoned, as well as the overall progress of strategy development and 
implementation over the course of the full period under review.   
2013 
pursuing opportunities aligned with vision 
and strategy 
organic growth 
 product portfolio 
 operational efficiencies 
 manufacturing excellence 
acquisitions 
 thoroughly planned and carefully 
executed 
aligned with the strategy 
transformed into a multinational 
company on the global stage 
strong and growing footprint in emerging 
markets 
manufacturing capability and supply 
chain competency 
 key enabler 
 critical advantage 
investment in future growth 
 property, plant and equipment 






value enhancing transactions 
 increased product portfolio 
extended geographic presence 
further specialised manufacturing 
capability 




organic growth opportunities 
key factor in creating incremental  
value 
manufacturing capabilities and capacity 
expansion and enhancement 
strategic advantage 
diversification strategy 
truly globalised company 
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The key words effectively painted a “strategy picture” of the business from which 







Figure 4.3 Aspen growth themes 
 
Up to this point, Aspen’s growth has been considered in terms of stated strategic 
objectives, key words and growth themes.  These elements could not however be 
studied in isolation and without a corresponding analysis of the actual growth of 
Aspen during the period under review.  At the core of the study was the growth of 
Aspen in financial terms, in relation to the generation by the company of positive 
and increasing revenue, profits and shareholder value.   
 
This required a selection and analysis of certain financial indicators, which are 
summarised in Appendix 3.  In order to view the figures visually, these indicators 






















2004 and 2014.  In addition, it made it possible to identify any above or below 
average results which could be further investigated to determine whether any 
growth strategies or challenges, which had given rise to such changes, could be 
identified.  The analysis of Aspen’s financial performance was therefore necessary 
to address the objectives of the study. 
 





Figure 4.4 Revenue 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
Revenue is money brought in by a company from goods sold.  Revenue is 
important in assessing the growth of a company as it shows whether the company 
is able to continually generate more sales over time.  Without revenue, a company 
is unable to cover its expenses, generate profits and stay viable in the long term 
(Kokemuller, no date).  
 
Figure 4.4 illustrates that:  
 
 Aspen sustained positive revenue growth throughout the period under 
consideration; 
 Between 2004 and 2008 the revenue growth was stable; 
 In 2009 the revenue almost doubled; 
 From 2010 to 2013 revenue grew by more than 20% per annum; and 
 In 2014 revenue increased by more than 50%. 












Figure 4.5 Operating profit 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
Operating profit is profit earned from the core operations of a business and reflects 
a company's ability to generate profit for its owners and shareholders 
(Investopedia, 2015). 
 
Figure 4.5 illustrates that:  
 
 Aspen sustained positive growth in operating profit throughout the period 
under consideration; 
 Between 2004 and 2008 the operating profit growth was stable; 
 In 2009 the operating profit almost doubled; 
 From 2010 to 2013 operating profit grew by more than 20% per annum; and 



















Figure 4.6 Earnings per share 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
Earnings per share is the portion of a company’s profit allocated to each 
outstanding ordinary share.  It is an indicator of the company’s profitability 
(Investopedia, 2015). 
 
Figure 4.6 illustrates that:  
 
 Aspen sustained positive growth in earnings per share throughout the 
period under consideration; 
 Between 2004 and 2008 the earnings per share growth was stable; 
 In 2009 the earnings per share grew by more than 50%; 
 From 2010 to 2013 earnings per share grew steadily; and 




















Figure 4.7 Headline earnings per share 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
Headline earnings per share are the earnings per share from the core operations 
of the business.  Headline earnings is a subset of total profits reported by a 
business which excludes ancillary transactions such as the sale of assets or a 
reduction in employees and therefore indicates profitability in respect of the day-to-
day operations of the business (Bragg, 2013).   
 
Figure 4.7 illustrates that:  
 
 Aspen sustained positive growth in headline earnings per share throughout 
the period under consideration; 
 Between 2004 and 2008 the headline earnings per share growth was 
stable; 
 In 2009 the headline earnings per share grew by more than 60%; and 
 From 2011 to 2014 headline earnings per share increased by more than 
















Figure 4.8 Market capitalisation at year-end 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
Market capitalisation is the total market value of a company’s outstanding shares 
and is calculated by multiplying the share price by the total number of shares in 
issue (in this case at year-end).  It is useful for determining the size of a company 
as well as the growth versus risk potential of the company (Investopedia, 2015). 
 
Figure 4.8 illustrates that:  
 
 The market capitalisation virtually doubled from 2004 to 2005 and grew by 
more than 50% in 2006; 
 The market capitalisation growth was muted in 2007 and decreased by 
more than 20% in 2008; 
 From 2008 to 2014 the market capitalisation grew positively but 
inconsistently; 
 In 2009 and 2010 the market capitalisation grew by approximately 60% and 
65% respectively; and 



















Figure 4.9 Share price at year-end 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
The share price at year-end is the market price of one share.  Once trading in a 
share starts, its price is largely determined by the forces of supply and demand.  
For example, a company which the market believes demonstrates long-term 
earnings potential is likely to attract more buyers, thereby increasing the share 
price (Investopedia, 2015).  
 
Figure 4.9 illustrates that:  
 
 The share price virtually doubled from 2004 to 2005 and grew by more than 
50% in 2006; 
 The share price growth was muted in 2007 and decreased by 
approximately 15% in 2008; and 


















Figure 4.10 Cash flow from capital expenditure – property, plant & 
equipment 2004 – 2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
This expenditure relates to the acquisition or upgrade of physical assets in the 
form of property, plant and equipment.  For a capital-intensive business such as a 
pharmaceutical manufacturer a large amount of capital investment in acquiring 
and maintaining such assets is necessary.  Current capital expenditure impacts 
future activities and may therefore be described as an investment a company in its 
future. 
 
Figure 4.10 illustrates that:  
 
 Capital expenditure on property, plant and equipment varied between R81 
million and R379 million during the period 2004 to 2008; 
 From 2009 the expenditure increased by 65% and remained over R600 
million for three consecutive years (2009, 2010 and 2011); 
 In 2013 the expenditure was again over R600 million; 
 In 2014 the expenditure nearly doubled this amount totalling R1.3 billion; 
and 
 During the period 2004 to 2014 a total of approximately R5,5 billion was 


















Figure 4.11 Cash flow from capital expenditure – intangible assets 2004 – 
2014 
Source: Compiled using Aspen company documents (2004 – 2014) 
 
This expenditure relates to the acquisition of intangible assets such as intellectual 
property rights.  Intangible assets are not physical assets in the sense that they 
cannot be seen or touched.  A company receives value from the right to use its 
intangible assets, examples of which include licenses, patents and trademarks. 
 
Figure 4.11 illustrates that:  
 
 Capital expenditure on intangible assets during the period 2004 to 2008 
was relatively consistent, ranging from R91 million to R166  million; 
 In 2009, 2012 and 2013 there were major increases in the expenditure to 
over R2 billion in each of these years; 
 In 2010 and 2014 the expenditure was R661 million and R700 million 
respectively; and 
 During the period 2004 to 2014 a total of approximately R11 billion was 
invested in intangible assets.  Approximately 80% of this total was spent in 




























Figure 4.12 Cash flow in Rands from acquisition of subsidiaries and 
businesses 2004 – 2014  
Source: Compiled using Aspen company documents (2004 – 2014) 
(Note: not to scale, for illustrative purposes only) 
 
These cash flows relate to the acquisition of subsidiaries and businesses and 
therefore the growth of a company in terms of expanding its presence and 
operations.  A subsidiary is a company already partly owned by the parent 
company and the acquisition would therefore represent acquisition of more or all of 
the shareholding in the subsidiary.  This may be contrasted to a business which is 
a separate entity acquired by the company. 
 
Figure 4.12 illustrates that:  
 
 Cash flow from the acquisition of subsidiaries and businesses during the 
period 2004 to 2007 was below R300 million each year, ranging from 
R100,000 to R268  million; 
 In 2008, 2011, 2013 and 2014 the cash flow exceeded R1 billion in each of 
these years; 
















Amounts over R1 
billion 
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 In 2014 the cash flow was R19.8 billion exceeding the total amount spent in 
the previous years from 2004 to 2014; and 
 During the period 2004 to 2014 the cash flow from the acquisition of 
subsidiaries and businesses totalled approximately R30 billion. 
 
4.5 Understanding the challenges 
 
The impressive growth shown by Aspen during the period under review, resulted 
in it delivering double-digit earnings growth to its shareholders for 16 consecutive 
years.  This was achieved despite the challenges presented by the industry and 
the markets in which Aspen operated at the time.   
 
The need to understand these challenges was required in order to address one of 
the objectives of the study, namely “What challenges has Aspen faced in 
implementing the growth strategies?”.  Identifying and analysing the challenges 
was intended to understand the environment in which Aspen operated.  The 
growth strategies adopted could not exist in a vacuum and were developed, 
implemented and altered in the context of Aspen’s business environment and 
operating conditions.  A comprehensive understanding of these challenges was 
therefore an important part of the study. 
 
From the comprehensive analysis of the Annual Reports issued by Aspen between 
2004 and 2014, key words were extracted relating to the challenges which Aspen 











deflationary pricing environment 
uncertainty created by changing legislation 
intense competition 
supply problems 
absence of new products 
2005 
legislation capped prices 
competitive market forces 
downward pressure on prices 
unable to fully service production demand 
increased competition 
complex regulatory compliance 
highly regulated sector 




intensity of competition 
global pressures 
downward pressure on generic prices 
dependence on third party suppliers 
interventions by regulators the world over 
meeting production demand 
high level of regulation and product 
liability risk 
products awaiting registration 
complicated regulatory compliance 
 
2007 
products awaiting registration 
uncertain legislative environment 
intensified generic competition 
regulatory intervention 
price cuts 
high level of regulation and product 
liability risk 
exposure to foreign exchange fluctuations 








dependence on third party suppliers 
re-scheduling of products 
stock write-off 
low rate of product registrations 
rising input costs 
high level of regulation and product 
liability risk  
exposure to changes in foreign currency 
and global interest rates  




















legislated price cut 
margin losses 
barriers to entry  
developing economies 
regulatory and cultural challenges 
raw material prices increased 
dependence on third party suppliers 
increase in production inflation whilst selling 
prices stayed fixed 
increasingly competitive market 
unfavourable change in the mix of relative 
exchange rates 
high level of regulation and product liability 
risk 
exposure to global interest rate movements 
complicated regulatory compliance 
2012 
challenging global market conditions 




pressure on medicine prices globally 
constant changes in healthcare 
legislation 
market specific risks  
2010 
generic sector remains intensely 
competitive  
low rate of product registrations 
political and economic circumstances 
pricing pressures 
high cost of labour 
global downward pressure on 
pharmaceutical prices  
greater competition from foreign suppliers 
exchange rate volatility 
2011 
highly regulated industry 
slow rate of product registration 
global pressure on the price of medicines 
constant changes in healthcare legislation 



























Figure 4.13 Understanding the challenges faced by Aspen through key 
words in the 2004 – 2014 Aspen Annual Reports 
Source: Compiled using Aspen company documents (2004 – 2014) 
 





increased pricing regulation 
volatile markets 





pressure on margins 
price cuts 
intense competition 
political instability  
lack of basic infrastructure 
complex trading and regulatory 
environment 
pressure on medicine prices globally 
constant changes in healthcare legislation 
currency volatility 





increased competition  
inflationary pressures 
rising costs 
shrinking operating margins 
pressure on medicine prices globally 
constant changes in healthcare 
legislation 
currency volatility 










This chapter presented the results of the case study analysis conducted in respect 
of Aspen.  Using the research methodology described in Chapter 3, Aspen’s 
publicly available Annual Reports, presentations and financial results were utilised 
as the data source.  Qualitative and quantitative data was extracted, analysed and 
presented in order to determine meaningful patterns and themes to assist in 
answering the research questions which were also set out in Chapter 3. 
  
The case study analysis revealed that Aspen adopted the following main growth 
strategies: 
 
 Organic growth – focusing on increased volumes and new products; 
 Inorganic growth – through carefully selected and strategic acquisitions of 















 Extending territorial coverage through global expansion, particularly into 
emerging markets; and 
 Ongoing investment in production capabilities as a means of achieving a 
strategic advantage. 
 
Such growth was achieved despite dealing with a number of challenges, including 
the following major industry and market-related challenges: 
 
 Intense competition; 
 Restrictive legislation; 
 Pressure on medicine prices; 
 Currency volatility; and 
 Market specific risks. 
 
These findings will be further discussed and explained in Chapter 5 in order to 










This chapter provides a discussion and analysis of the research results from the 
case study which are set out in Chapter 4.  Using the theoretical framework set out 
in Chapter 2, the analysis of the research results is aimed at answering the 
research questions posed in Chapter 3.  
 
Growth is the key to the long term success of a business, being a prerequisite for 
increasing revenue, profits and shareholder value (Strategic Direction, 2006; 
Bürkner, King and Razali, 2013).  As a result, having a carefully formulated growth 
strategy, which is appropriate to the company and takes into account the 
importance of execution and integration, is fundamental to achieving sustainable 
growth. 
 
In the period of 11 years between 2004 to 2014, Aspen’s revenue grew from R2,2 
billion (2004) to R29,5 billion (2014) and its operating profit from R554 million 
(2004) to R7,4 billion (2014), interestingly both representing an increase of 
approximately 1240%.  Achieving such impressive growth in an industry faced with 
pricing and cost pressures, stringent regulations and shrinking margins in both 
mature and emerging markets (Roland Berger, 2013) warranted a closer analysis. 
 
This chapter is therefore aimed at unpacking the research results which the case 
study analysis gave rise to in Chapter 4, in order to determine the growth 
strategies adopted by Aspen as well as the challenges faced by it in implementing 
such strategies.  Following from this, consideration is given to the learnings which 







5.2 Research question 1: growth strategies adopted by Aspen 2004 – 
2014 
 
The growth themes identified in Chapter 4 are used as the framework for 
analysing the growth strategies adopted by Aspen. 
 
5.2.1 Organic growth 
 
“…Aspen recognises that organic growth provides the most effective return on 
investment. …The product pipeline is critical to the future sustainability of the 
Group, providing opportunities to bring new products to the market and growing 
Aspen’s presence in addition to compensating for any products in decline in the 
existing portfolio. The product pipeline is a most valuable asset…” (Aspen, 2009, 
p. 26). 
 
Organic growth is achieved when a company grows from within.  Many of Aspen’s 
stated strategic objectives illustrate its recognition of the importance of maintaining 
organic growth: 
   
 increasing investment in new product development; 
 continually commercialising new pharmaceutical products; 
 ability to source and launch new product pipeline; 
 first to market in new product launches; 
 sourcing and launching the new product pipeline; and 
 robust product pipeline for targeted strategic regions. 
 
(Aspen company documents 2004 – 2014) 
 
The company therefore placed much focus on developing and maintaining a 
strong product pipeline as a form of core growth aimed at selling more products to 
more customers in order to increase revenues.   
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Aspen also recognised that whilst “(r)evenue growth is an important factor in 
market share advancement and protection…without an acceptable margin of 
profit, growth in revenue alone is not a sustainable strategy” (Aspen, 2010, p. 74).  
As a result, profit generation was a primary objective in the pursuit of growth.  
 
This positive and sustained revenue growth and profit growth are apparent from 
Figure 4.4 and Figure 4.5 in Chapter 4, which are reproduced below with 
highlighting for illustrative purposes. 
 
                                         
 
One of the ways in which profitability was achieved was through operational 
strategies which focused on manufacturing capacity and optimising production 
efficiencies.  The effect of this was twofold: (i) with increased volumes, the supply 
of products was able to meet demand, and (ii) by realising economies of scale, 
both the recovery of fixed costs and profit margins were improved. 
 
5.2.2 Inorganic growth 
 
Aspen did not only focus its efforts on organic growth.  Simultaneously it set out to 
supplement organic growth with strategic product and business acquisitions, with 
stated strategies including: 
 
 acquisitive growth; and 
 assessing acquisitive opportunities. 
 
Inorganic growth through acquisitions, effectively allows a company to purchase 
growth “off-the-shelf” (Ward, 2015).  Whilst the access to new products and new 
markets is an attractive prospect for an acquiring company, the literature sets out 
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the drawbacks of such a growth strategy.  These include the high cost, particularly 
in what Megget (2015) describes as the current “M&A frenzy” of competition for 
valuable assets in the pharmaceutical industry.  In addition the integration of the 
acquired product or business often poses a major challenge to the extent that 
Grant (2013) describes the selection and integration of acquisitions as an 
organisational capability in itself. 
 
Aspen’s approach to acquisitions appears to take all of these factors into account: 
 
 “The acquired businesses and products bring immediate added value to 
Aspen’s earnings potential as well as providing the infrastructure to allow a 
continuation of growth into the next decade” (Aspen, 2008, p. 21); 
 
 “The absence of material acquisitions over the past year has been a 
consequence of unrealistic pricing preventing the conclusion of deals which 
represent value rather than a lack of ambition in this regard” (Aspen, 2007, 
p. 15); and 
 
 Effectively integrating acquisitions into the business and adopting Aspen’s 
corporate culture (by new management and employees) is recognised as a 
key strategic risk which requires focused mitigation activities (Aspen, 2012). 
 
One of the key factors in Aspen identifying and assessing acquisitive opportunities 
was the need for them to be aligned with its business strategy.  As a result, 
Aspen’s product and business acquisitions may be described as strategic and a 
closer inspection reveals the strategic intent behind them: 
 
 Vertical integration: recognising the benefits of vertical integration, which 
allows for greater control over the quality and cost of supply of raw materials, 
Aspen made a number of key acquisitions in pursuit of this strategy.  These 
included: 
 
- the acquisition of Fine Chemicals Corporation (50% in 2004 and the 
remaining 50% in 2009) as a supplier of key APIs; and 
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- a number of strategic acquisitions in 2014 positioning Aspen as a leading 
global player in anticoagulants (these included the acquisition of products, 
a specialised production site which manufactures certain of these brands 
as well as a manufacturing business which supplies the raw material for 
certain of the brands acquired – thereby creating the opportunity to 
harness benefits from vertical integration). 
 
 Niche and specialised products: Aspen made a number of acquisitions in the 
pursuit of differentiation from competitors and the access to profitable niche 
markets with high barriers to entry.  These included:  
 
- the building of specialist knowledge and capabilities in the infant nutritional 
business (2004 acquired the Infacare brand and manufacturing facility in 
South Africa, 2013 acquired the license rights in Australia and certain 
territories in southern African (including South Africa) from Nestlé, and 
2014 acquired license rights and a production facility in Latin America from 
Nestlé); 
 
- the acquisition of certain products in niche areas of highly specialised 
treatments from GSK in 2008; 
 
- the acquisition from GSK in 2009 of eight specialist branded products for 
distribution worldwide; and 
 
- the 2014 anticoagulant acquisitions mentioned above related to products 
with few or no competitor products. 
 
The extent and impact of Aspen’s acquisitive growth strategy is apparent from a 
closer inspection of Figure 4.12, 4.11, 4.4 and 4.5 respectively in Chapter 4, as 


























From Figure 4.12 it can be seen that the first 
major spike in acquisition expenditure 
occurred in 2008, exceeding R1 billion, when 
Aspen acquired an interest in businesses in 
East Africa and Latin America. 
 
In 2011 the expenditure was close to R6 billion 
when Aspen acquired the pharmaceutical 
business of Sigma Pharmaceuticals Limited 
(based in Australia). 
 
In 2014, the expenditure soared to nearly R20 
billion as Aspen undertook a number of 
“transformational transactions” (Aspen, 2013, 
p. 30), including the anticoagulant and infant 
nutritional acquisitions mentioned above. 
In respect of the acquisition of intangible 
assets, from Figure 4.11 it is apparent that the 
major purchases took place in 2009 (eight 
specialist branded products to be distributed 
worldwide) and 2013 (a portfolio of 25 
branded pharmaceutical products to be 
distributed in the Australian market) in respect 







These increases suggest that the acquisition expenditure contributed positively to 
the increase in revenue and profits, which demonstrate the positive effects of the 
inorganic growth strategy adopted. 
 
It is thus evident that Aspen recognised that its expansion objectives could be 
well-served by acquisitions and it sought to acquire value enhancing products and 
businesses which were aligned to the Group’s business strategy (Aspen, 2006). 
 
5.2.3 Global expansion  
 
The literature recognises that internationalisation offers vast opportunities to 
companies in the pursuit of growth (Lessard, Lucea and Vives, 2012).  Aspen 
shared this view as indicated in its stated internationalisation strategy: 
 
 expansion into new markets; 
 transforming the organisation for international growth; and 
 expanding into new markets, with a specific emphasis on emerging 
markets. 
 
(Aspen company documents 2004 – 2014) 
 
It should be noted that Aspen’s revenue 
(Figure 4.4) increased by 80% in 2009, the 
year following the first major spike in 
acquisition expenditure.  Revenue continued 
along this positive growth path, peaking at 
R29,5 billion in 2014. 
 
Similarly, Aspen’s operating profit (Figure 4.5) 
increased by 82% in 2009 and continued 
growing, peaking at R7,4 billion in 2014. 
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In addition to the creation of opportunities for business growth, Aspen diversified 
its business into international markets in order to mitigate the risk of exposure to a 
single market (Aspen, 2010).  Aspen’s reliance on its domestic South African 
market was reduced through its geographic diversification, thereby spreading 
market risk and increasing the scope for robust and sustainable financial growth 
(Aspen, 2010).  
 
From being a predominantly South African business in 2008, Aspen transformed 
into a diversified global business by 2012, when the profits generated by Aspen’s 
International businesses exceeded those from the South African business for the 
first time (Aspen, 2012). 
 
The approach followed by Aspen was a combination of acquisitive and organic 
growth in respect of both territory and product expansion.  This commenced in 
2008 with investments in businesses in Latin America (Brazil, Mexico and 
Venezuela) and East Africa (Kenya, Tanzania and Uganda) as well as a variety of 
product acquisitions which opened up a number of new global markets.  
Strategically, entities were established as hubs to manage the commercial 
activities of the international ventures (in Mauritius) and relevant regions such as 
EMENAC (in Dubai). 
 
Entities were also established in Hong Kong (2010), Philippines (2012), Taiwan 
(2013), Malaysia (2013) and Japan (2014) as part of the establishment of a 
footprint in the Asia Pacific region. 
 
The 2014 infant nutritional acquisition from Nestlé brought about expansion in 
Latin America (such as Colombia, Chile, Ecuador and Peru), whilst the 2014 
anticoagulant transactions gave rise to expansion in Europe with business units 











These increases suggest that the global expansion contributed positively to the 
increased revenue and profits, which demonstrate the positive effects of the 
internationalisation strategy adopted.  
    
Certain key elements of Aspen’s internationalisation strategy should be 
highlighted: 
 
 Building an international business from a solid base: Aspen’s initial focus was 
on building a successful and stable domestic operation in South Africa.  From 
the strength of this foundation it built its multinational business. 
 
The need to mitigate the risk of exposure to a single market was recognised 
by Aspen as early as 2001 when it entered the Australasian market.  From 
These expansion activities are apparent from 
Figure 4.12 in Chapter 4, reproduced with 
highlighting for illustrative purposes.  The 
major acquisitions resulting in territory 
expansion occurred in 2008 and 2014, as 
discussed above. 
Again it may be noted that Aspen’s revenue 
(Figure 4.4) increased by 80% in 2009, the 
year following the first major spike in 
acquisition expenditure which included the 
acquisition of businesses in other territories 
(ie. global expansion).   
 
Similarly, Aspen’s operating profit (Figure 
4.5) increased by 82% in 2009.   
 
These increases suggest that the 
acquisition expenditure contributed 
positively to the increase in revenue and 
profit,s which demonstrate the positive 





inception, the Australian business successfully delivered sustained growth.  
On the strength of this established base it was able to acquire the 
substantially larger pharmaceutical business of Sigma Pharmaceuticals 
Limited in 2011. 
 
Once it had established a leading position in the South African 
pharmaceutical market, Aspen diversified its geographic presence by 
expanding to territories outside South Africa. 
 
As a result, the Group’s global expansion was anchored by the two large, 
mature concerns in South Africa and Australia, each with a leading market 
position and an ability to efficiently convert profits into cash.  Today South 
Africa remains the foundation of the business with its Group headquarters 
situated there. 
 
 Emerging markets: Emerging pharmaceutical markets, so called 
“pharmerging markets”, are considered to offer significant growth 
opportunities for pharmaceutical companies (McKinsey & Company, 2012).  
Aspen recognised this and, in increasing its global footprint, concentrated on 
emerging markets where robust growth was anticipated. 
 
Aspen’s willingness to deal with the challenging trading conditions and 
barriers to entry which were generally present in these pharmerging markets 
was largely based on the fact that the characteristics of the selected markets 
had much in common with South Africa (such as a growing population, an 
increasing number of the aged, an expanding middle class which is 
vulnerable to lifestyle diseases and has an increased awareness of brands, 
price and quality) (Aspen, 2009). 
 
As a result, Aspen applied the essential components of the approach which 
had been successful in South Africa in order to establish growing and 
profitable businesses in these markets (Aspen, 2009).  Such elements 
included supplying a broad-range portfolio of high quality medicines at 
102 
affordable prices, together with an extensive sales representation and 
excellent service delivery. 
 
 Glocalisation: (a combination of the words globalisation and localisation) is a 
recognition of the need to integrate local elements into global products in 
order to increase the likelihood of a product succeeding in a new market 
(Matusitz, 2010).   
 
Aspen focused on the need to offer products which were relevant to each 
region in which it operated.  As a result, the selection of products for the 
pipeline received close attention in an attempt to identify products which were 
appropriate for the specific markets and addressed the disease profiles of 
each region (Aspen, 2012).  This careful combination of global 
standardisation and local adaption involved balancing the efficiency 
opportunities of global scale with the need for local differentiation (Matusitz, 
2010). 
 
 Modes of market entry: Aspen’s entry into foreign markets developed from 
low company resource commitment of export and licensing arrangements to 
higher resource commitment in the form of joint ventures and wholly owned 
subsidiaries.   
 
Aspen’s entry into Latin America and East Africa in 2008 was facilitated 
through investment in existing local companies.  It took full control of these 
businesses in 2010 and 2012 respectively.  This approach allowed Aspen to 
gain insight into the regions and businesses before deciding whether to fully 
invest.   
 
Aspen’s entry into Asia Pacific was through the formation of subsidiaries and, 
as previously mentioned, this was from the base of the established Australian 
business which facilitated expansion into the region.  The entry into Europe 
was facilitated by the acquisition of the anticoagulant products and facilities, 
which then gave rise to the establishment by Aspen of business units across 
Europe. 
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Aspen’s mode of foreign market entry thus varied depending on the nature of 
the market and was tailored to mitigate the risks posed and take advantage 
of the opportunities available in each territory. 
 
5.2.4 Investment in production capabilities 
 
One of Aspen’s stated strategic objectives is “to achieve a strategic advantage 
through our production capabilities” (Aspen, 2014, p. 4).     
 
This is evident from the fact that, in addition to the investment in businesses and 
products, Aspen pursued profit and growth through the continual expansion and 
improvement of its production facilities and methods.   
 
Figure 4.10 in Chapter 4, reproduced below with highlighting for illustrative 







The continual investment in property, plant and equipment was aimed at 
increasing capacity, diversifying and increasing capabilities, as well as expanding 
into specialised areas of manufacture.  This investment in manufacturing capability 
was intended to provide the Group with the ability to pursue its growth objectives 
(Aspen, 2007). 
 
The positive and sustained revenue growth and profit growth are apparent from 
Figure 4.4 and Figure 4.5 in Chapter 4, which are reproduced below with 
highlighting for illustrative purposes. 
From 2004 to 2008 approximately R1 billion was 
spent on property, plant and equipment.  A 65% 
increase in expenditure from 2008 to 2009 marked 
the start of three years of investment exceeding R6 
million per annum.  In 2014 expenditure peaked at 
R1,3 billion, resulting in the total investment over 
the 11 year period from 2004 to 2014 being 
approximately R5,5 billion. 
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This constant growth suggests that the investment in production capabilities 
contributed positively to the increased revenue and profits, which demonstrates 
the positive effects of this growth strategy.  
 
Developing these manufacturing capabilities into a core strength had a number of 
positive repercussions for Aspen: 
 
 created a catalyst for international expansion; 
 transformed Aspen from a domestic producer to a manufacturer with the 
capability to supply a variety of products to markets around the world; 
 became an important supplier to the Group’s international business; 
 positioned the Aspen Group as a quality manufacturer of the highest 
international standards, providing an ability for the Group to engage with a 
number of the world’s leading pharmaceutical organisations from which 
business collaborations could be developed; 
 maintained gross margins in spite of the general pressure to reduce selling 
prices; and 
 facilitated the critical mass offered by high volume manufacture resulting in 
reduced cost of goods and profit improvement. 
 
(Aspen company documents 2004 – 2014) 
 
Through Aspen’s continual investment in its production capacity and capabilities, it 
developed its manufacturing into a core competence.  This created a competitive 
advantage and resulted in above average organisational performance, allowing 
Aspen to pursue growth through increased profitability and expansion. 
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5.2.5 The strategy behind the growth 
 
The growth achieved by Aspen between 2004 and 2014 is indicative of a high 
performance organisation.  Such growth, attained through organic and inorganic 
means as well as global expansion and the development of manufacturing as a 
critical business asset, did not occur by chance.  It would therefore be remiss not 
to mention the effective formation and implementation of strategy which 
underpinned such growth. 
 
A number of the theories underlying the concept of strategy can be identified in 
Aspen’s development, such as: 
 
 investing in strategically valuable resources (physical assets, intangible 
assets or capabilities) to obtain a competitive edge over rivals (Collins and 
Montgomery, 2008); 
 reacting opportunistically to emerging possibilities (Ovans, 2015); 
 intentionally selecting a distinctive array of activities in order to provide a 
unique combination of value (Porter, 1996; Harrison and St. John, 2014); and 
 selecting a strategic position by identifying which activities are incompatible 
and purposefully limiting what the company offers (Porter, 1996; Hunter, 
2014) (here note the divestments referred to in Appendix 2, which illustrate 
the trade-off decisions made by Aspen); 
 
The literature on strategy suggests that leadership is at the core of strategy 
(Edinger, 2013) and that the challenge of developing a clear strategy is dependent 
on leadership (Porter, 1996; Clegg et al., 2011).  Such strategic leadership was 
demonstrated by Aspen’s top management team who: 
 
 recognised the importance of maintaining organic growth as a key factor in 
creating incremental value; 
 identified strategic acquisitive opportunities to supplement organic growth, 
particularly those which could differentiate Aspen from its competitors and 
which were a “strategic fit” for the business; 
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 identified an internationalisation strategy, with a particular focus on 
emerging markets, as a means of mitigating the risk of being exposed to a 
single market and creating opportunities for business growth; and 
 built its manufacturing capabilities into a core competence through 
continuous investment and development, thereby creating a competitive 
advantage. 
 
Many of the growth strategies adopted by Aspen were in keeping with the trends 
identified in the studies on the pharmaceutical industry as set out in Chapter 2.  
Whilst Aspen’s approach was thus not unique, as the largest pharmaceutical 
company listed on the Johannesburg Stock Exchange (South African stock 
exchange), it managed to outgrow and outperform its South African 
pharmaceutical competitors which, it could be argued, were competing in the 
same marketplace and had the same growth strategies available to them.   
 
Whilst the growth strategies were thus not unique to Aspen, what the theory and 
case study results perhaps do not capture are the less concrete concepts 
underlying such growth.  Innovative, passionate, logical, dedicated and 
persevering are all words which could be used to describe the characteristics of 
the skilled and experienced leadership and management which crafted and 
executed Aspen’s strategy across multiple territories and in so doing guided Aspen 
along its growth path.  The balance of entrepreneurialism and sound business 
fundamentals is at least one factor which set Aspen apart from its South African 
competitors. 
 
5.3 Research question 2: challenges faced by Aspen in implementing its 
growth strategies 
 
As a generic pharmaceutical company, Aspen faced a number of challenges in 
implementing its growth strategies.  Initially, as a predominantly South African 
company, these challenges were largely country specific however as Aspen 
expanded into global markets, similar challenges were met in other territories as 
well as challenges unique to those markets. 
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5.3.1 Intense competition 
 
One of the major challenges faced by Aspen was competition.  Whilst competition 
is neither unique to the pharmaceutical industry nor to South African companies, 
the generic pharmaceutical industry as well as the global pharmaceutical industry 
in general are characterised by intense competition (Deloitte, 2014).  In particular, 
the number of generic companies competing with the launch of a product upon 
patent expiry of a molecule as well as the presence of low-cost Asian 
pharmaceutical companies in all key territories increases the level of competition 
in the generic pharmaceutical market space (Aspen, 2014). 
 
5.3.2 Restrictive legislation 
 
As the global pharmaceutical industry is characterised by a complex and evolving 
regulatory landscape, legislation posed another challenge to Aspen.  Regulatory 
control aimed at protecting consumers’ health and safety takes the form of quality 
regulations, which requires a pharmaceutical company to submit its products for 
registration with the relevant regulatory authority.  Such submission must include 
proof of feasibility and efficacy of a product, as well as proof that the 
manufacturing capability exists to supply the product (Aspen, 2010).  This process 
can take many years and therefore affects the launch date of the product in the 
relevant market. 
 
Pharmaceutical products must be registered in each market in which they are sold.  
Aspen initially faced challenges only with regard to the South African Medicines 
Control Council and encountered major delays in the registration of its products, at 
times with more than 200 products awaiting registration.  Following global 
expansion, Aspen had to deal with the challenge of registering its products in 







5.3.3 Pressure on medicine prices 
 
Another form of regulatory control is aimed at containing the costs of medicines 
through price regulations.  This links to another challenge which Aspen faced, 
namely the pressure on medicine prices.  In South Africa and most other countries 
worldwide, regulators seek to reduce the cost of pharmaceuticals through pricing 
legislation (Deloitte, 2014).  This challenge was thus not unique to Aspen, nor to 
the South African pharmaceutical industry.  Working within mandated price 
increases or price cuts, coupled with rising input costs presented an ongoing 
challenge to Aspen, requiring initiatives to improve cost competitiveness and 
protect profit margins (Aspen, 2011). 
 
5.3.4 Currency volatility  
 
With globalisation, comes an increase in the exposure to multiple currencies.  
Exchange rate fluctuations can have an effect on companies whether they are 
small, medium or large in size and whether they are multinationals or operate only 
in their home country (Picardo, 2014).  Such currency volatility was another 
challenge faced by Aspen.  Prior to its global expansion, Aspen was chiefly 
concerned with the strength of the Rand relative to other currencies insofar as it 
impacted on import and export costs.  However, increasing its geographic 
representation and conducting business in multiple currencies meant that Aspen 
also had to deal with an increase in currency exposure which could have an 
influence on its operations and potentially a major influence on its profitability.   
 
Entering into a number of transactions for the acquisition of foreign businesses 
and assets with an obligation to make payments in foreign currency meant that 
Aspen was exposed to the risk of exchange rate fluctuations, so called 
“transaction exposure” (Picardo, 2014; Ajami and Goddard, 2015).  In addition, 
having foreign subsidiaries meant that Aspen was exposed to the effect of 
currency fluctuations particularly in respect of the consolidation of financial 
statements so called “translation exposure” (Picardo, 2014; Ajami and Goddard, 
2015).   
 
109 
Whilst Aspen’s company management could estimate the extent of the above 
types of currency exposure, another challenge was presented by unexpected 
currency fluctuations, being “economic exposure” (Picardo, 2014; Ajami and 
Goddard, 2015).  As budgets and forecasts are prepared based on certain 
assumptions about exchange rate movements, unexpected currency rate changes 
pose a serious risk as they are not provided for and can therefore substantially 
impact a company’s cash flows and market value (Picardo, 2014). 
 
5.3.5 Market specific risks 
 
One of the major challenges which Aspen had to deal with as it expanded into new 
territories was market specific risks.  Dealing with the regulatory, cultural and 
political challenges in different markets required an in-depth understanding of the 
nature of each territory in order to determine how to overcome the hurdles 
presented, and ensure that the business model could succeed in such 
environment. 
 
The literature recognises that global expansion into foreign markets brings with it 
the risks and uncertainties of the new market’s economic and political stability, 
infrastructure, taxation, regulations and cultural barriers (Rynd, 2015). 
 
From an analysis of the Aspen company documents, some of the market specific 
risks faced by Aspen, in the territories where it had established a presence, were 
identified.  These are set out below: 
 
 Developed markets:  weak growth mainly due to an increase in pricing 
regulation; general pressure on the growth of the economy in these markets; 
 Emerging markets: difficult trading conditions and barriers to entry; 
 Asia: a variety of environments in the Asian countries (including economic, 
social, cultural, legal and political differences); 
 Australia: aggressive legislated price cuts, increased competition and resulting 
stagnant market; 
 Brazil: unpredictable and lengthy product registration timelines; 
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 Europe: pricing pressures and high cost of labour; 
 Latin America: complicated market in the operating and regulatory setting 
which is unique to each territory (multiple individual markets); barriers to entry 
and cultural challenges; 
 MENA: individually regulated countries with healthcare at different levels of 
development; challenging to navigate; political unrest in some countries; 
 South Africa: regulated price increases; weakening currency; inflationary 
pressures; energy costs; long product registration timelines; 
 SSA: political instability; lack of infrastructure; complex regulatory 
requirements as well as inconsistency in the registration requirements of the 
regulatory body in each country; unstable economic climate; differing 
commercial, cultural and legislative conditions in each country; counterfeit 
products able to easily enter certain markets; and 
 Venezuela: challenging economic and political environment; devaluation of the 
currency. 
 
(Aspen company documents 2004 – 2014) 
 
5.3.6 Common challenges 
 
A study of the literature in Chapter 2 revealed that the pharmaceutical industry is 
characterised by intense global competition, increasing regulatory pressure to 
reduce medicine prices, restrictive legislation, slowing growth in developed 
markets and challenging market conditions in the emerging markets (Deloitte, 
2014).  It is therefore evident that the challenges faced by Aspen in implementing 
its growth strategies were not unique to the company.  This fact did not however 
make overcoming the challenges any easier.  Thorough market research, strategic 
planning, and a focus on optimising cost competitiveness were required to ensure 
that, in the face of these challenges, the company succeeded in the global 





5.4 Research question 3: learnings other companies can take from the 
case study analysis of Aspen 
 
Against the background of the first two research questions, analytic generalisation 
was used to generalise the findings to other situations.  Such generalisations are 
not intended to be conclusive but instead provide a theoretical proposition which 
could be investigated through further research or case studies to determine 
categorical findings (Yin, 2012). 
 
The suggested learnings which other companies can take from the case study 
analysis are set out below. 
 
5.4.1 The importance of strategy and strategic leadership 
 
A key learning from the case study analysis of Aspen is the importance of effective 
strategy formulation and implementation, as well as the significance of strategic 
leadership. 
 
A strategy is critical to the existence and future of a company.  This includes the 
company choosing the distinctive set of activities which it will perform to deliver a 
unique mix of value, as well as determining which activities it will not perform 
(Porter, 1996; Tanwar, 2013.  In identifying which activities are incompatible and, 
in so doing, purposefully limit what the company will offer, a strategic position must 
be selected (Porter, 1996; Hunter, 2014). 
 
Having a strategy is not in itself sufficient.  The strategy must then be effectively 
implemented.  This requires that the company performs its activities well and 
integrates them to ensure that there is “fit” amongst them – in so doing a 
distinctive strategy may be created (Porter, 1996; Hunter, 2014). 
 
Leadership is key to this strategy formulation and implementation, and strategic 
leadership (which includes visionary leadership) is required to identify and realise 
significant opportunities (Hsieh and Yik, 2005).  Through its top management 
team, a company must make strategic choices about the path which the company 
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will take and how competitive advantage will be created and enhanced.  It is thus 
through the choices made by its strategic leadership that superior organisational 
performance may be achieved (Lear, 2012). 
 
5.4.2 The value of organic growth 
 
In the quest for growth, companies should not lose sight of the importance of 
organic growth, being true growth from the core of a company.  As a permanent 
opportunity available to a company through a focus on the leveraging of resources 
and capabilities to optimise existing customer relationships, it offers a faster and 
less risky short-term return on investment than external growth (Mognetti, 2002). 
 
It is important that a company continuously strives to optimise organic growth and 
in so doing ensures that it uses its internal resources to expand profits.  As a 
feasible driver of value creation, organic growth should not be overlooked in 
creating sustainable growth for a company. 
 
5.4.3 The need to leverage core competencies to create a sustainable 
competitive advantage  
 
The case study analysis of Aspen highlights the importance of an organisation 
identifying what it does well and building on such strength to the level of a core 
competence which can provide a competitive advantage over its competitors 
(Ovans, 2015). 
 
A core competence, in the form of a resource or capability, can provide stability to 
an organisation and make organisational growth possible (Hindle, 2008).  An 
existing core competence or the potential for one may be identified.  A company 
can then determine what resources are required to elevate the core competence 
to the level of a distinctive advantage over competitors thereby creating a unique 
competitive position for the company (Porter, 1996; Clegg et al., 2011).  A 
company should also try to determine the underlying cause of a competitor’s 
strengths in order to determine what its core competencies are (Prahalad and 
Hamel, 1990). 
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5.4.4 Acquisitions: the importance of strategic fit and integration  
 
If a company wishes to expand through acquisitions, either in the form of products 
or businesses, two important elements may be identified from the case study 
analysis of Aspen – these are strategic fit and integration. 
 
In order for an acquired product or business to be value enhancing it is essential 
that it is compatible with the acquiring company’s business model and aligns with 
its business strategy.  This is an ongoing exercise and means that, whilst an 
acquisition may have initially been a good investment, as the business strategy 
and focus changes over time, it is important to identify those assets which no 
longer align with the company’s strategic intent. 
 
An example of this is Aspen’s focus in the consumer division on the acquisition of 
products such as soap, toothpaste and deodorant around 2004 and 2005.  Over 
time Aspen’s focus shifted to its infant nutritionals business and, during 2010 and 
2011, the consumer products were divested in a concerted move to leave the 
personal care segment (Aspen, 2011).  Recognising that the personal care 
products were no longer a strategic fit with the business allowed Aspen to adopt a 
more focused approach and move towards building leadership in specific 
categories and capabilities. 
 
The second element of integration is also crucial to ensuring the successful and 
profitable inclusion of a new product or business into the acquiring company.  
Effective integration requires intensive planning and preparation. 
 
Where a business is acquired, the integration is required on multiple levels 
affecting all aspects of the business – such as people, products, processes, 
systems and strategic objectives.  These include: 
 
 management culture and structures; 
 internal controls (including financial reporting controls); 
 employee deployment; 
 IT systems; and 
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It is important that the acquired business understands and implements the 
practices and policies of the acquiring company.  Thus strategic and cultural 
alignment of the new business and its leaders with the business objectives of the 
organisation is essential and this may be achieved through the preparation and 
application of a detailed integration plan (Aspen, 2011). 
 
The acquisition of products also requires intensive planning for operational 
integration.  This relates to aspects such as: 
 
 quality systems; 
 logistics; 
 manufacturing requirements; 
 manufacturing capacities and demands; and 




5.4.5 Expanding internationally: building from a solid base, selecting the 
right strategy and careful planning 
 
Internationalisation presents new markets, new customers and vast opportunities 
to many companies and is thus an attractive option in the pursuit of increased 
profits and growth (Lessard, Lucea and Vives, 2012).  Such expansion is however 
complex and the Aspen case study illustrates the importance of carefully 
formulating and implementing strategies for competing globally. 
 
Firstly, building the business from a solid successful base in South Africa allowed 
Aspen to seek global opportunities.  In particular, its ongoing investment in its 
manufacturing capabilities, elevating them to the level of a critical strategic asset, 
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allowed the company to set out on its path of international expansion.  In Aspen’s 
December 2008 Interim Results presentation the company states that “without our 
(South Africa) operations, our international aspirations would have stayed a 
dream” (p. 35). 
 
Secondly, the case study of Aspen illustrates the importance of selecting the right 
market entry strategy as well as the establishment of systems and structures to 
support the business expansion. 
 
With a combined approach of (i) strategic joint ventures, (ii) acquisitions, and (iii) 
the establishment of new entities, the Aspen business grew into a transnational 
organisation which combined the capabilities of the independent subsidiaries in 
the various territories around the world with the coordination of operations at a 
central level at the headquarters in South Africa (Bartlett, 1986).  This allowed the 
company to be simultaneously responsive to national differences and globally 
efficient and competitive (Bartlett and Ghoshal, 2002). 
 
Finally, careful planning is an essential element in an internationalisation strategy, 
particularly with regard to selecting the territories and markets.  The case study 
illustrates how Aspen strategically selected products, businesses and territories 
following extensive research.  Companies wishing to expand internationally need 
to have a thorough understanding of the market dynamics of the regions which 
they are considering entering.  This will allow them to determine the attractiveness 
of the market and whether the company will be able to establish a competitive 




This purpose of this chapter was to discuss and analyse the research results from 
the case study, which are set out in Chapter 4, with the objective of answering the 




Through an analysis of the qualitative and quantitative data presented in Chapter 
4, the study sought to identify and analyse the growth strategies adopted by Aspen 
between 2004 and 2014.  In addition, the study set out to determine what 
challenges Aspen faced in implementing its growth strategies.   
 
Finally, through analytic generalisation, the study sought to ascertain what 
learnings other companies can take from the case study analysis of Aspen. 
 
Chapter 6 brings the study to a close with concluding comments including the 
proposal of a model for sustainable growth, a consideration of the limitations of the 




Conclusion and Recommendations 
 
“Aspen’s strength lies in its understanding of the dynamic markets in which 
it operates and identifying and pursuing opportunities that align with the 




Aspen began trading in 1997 and, since listing on the Johannesburg Stock 
Exchange in 1998, has delivered double-digit earnings growth to its shareholders 
for 16 consecutive years.  Aspen was ranked tenth in the Forbes’ 2014 list of “The 
Top 25 Most Innovative Companies in the World” (Aspen, 2014, p. 27).  In the 
same year, Aspen was one of four South African companies included on the 
Boston Consulting Group’s list of “100 Global Challengers.”   This list recognises 
companies from emerging markets that are “growing so quickly overseas that they 
are reshaping industries and surpassing many multinational companies” (Aspen, 
2014, p. 27).   
 
The phenomenal growth achieved by Aspen over the past 11 years (2004 – 2014) 
was considered a worthy subject for a case study analysis.  Aspen’s growth is 
impressive particularly in the context of (i) the intensely competitive and highly 
regulated global pharmaceutical industry, (ii) the challenges faced by South 
African companies trying to establish themselves in the global marketplace, (iii) 
established multinational companies dealing with the challenges posed by 
stagnant developed markets and complex emerging markets.  The main aim of 
this study was therefore to understand how this growth was achieved by Aspen. 
 
This concluding chapter sets out the implications of this research and summarises 
the conclusions to the research questions.  Based on these conclusions, a model 
for sustainable growth was developed and is presented.  The limitations of the 
study are identified and recommendations for future research provided. 
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6.2 Implications of this Research 
 
The main purpose of this study was to identify and analyse the growth strategies 
adopted by Aspen, as a global pharmaceutical company, during the period from 
2004 to 2014.  In order to understand the context in which this growth occurred, it 
was considered necessary to also ascertain what challenges Aspen faced in 
implementing these growth strategies.  In an attempt to generalise these findings, 
the study also sought to determine what learnings other companies could take 
from the case study analysis of Aspen.  
 
Using the theoretical framework set out in Chapter 2 and the research 
methodology outlined in Chapter 3, the case study data presented in Chapter 4 
was analysed and discussed in Chapter 5.  Through this case study analysis of 
Aspen, the research questions have been answered.  Based on the answers to the 
research questions, a model for sustainable growth was developed.   
 
The study aims to contribute to the broader theory on business growth strategies.  
In addition, it proposes that companies (particularly South African pharmaceutical 
companies) may use the sustainable growth model which has been developed, as 
part of their strategic planning process for growth. 
 
6.3 Conclusions to the Research Questions 
 
6.3.1 Research question 1: What growth strategies has Aspen adopted 
over the past 11 years (2004 – 2014)? 
 
The study found that, guided by strategic and visionary leadership, the following 
central growth strategies were adopted by Aspen during the period under review: 
 
 organic growth, being a key factor in creating incremental value for Aspen 
and its stakeholders; 
 inorganic growth, through thoroughly planned and carefully executed 
acquisitions aligned to the Group strategy; 
119 
 extending territorial coverage through global expansion, with a focus on 
emerging pharmaceutical markets; and 
 ongoing investment in production capabilities as a means of achieving a 
strategic advantage.   
 
6.3.2 Research question 2: What challenges has Aspen faced in 
implementing the growth strategies? 
 
The study identified and discussed the following challenges: 
 
 intense competition; 
 restrictive legislation; 
 pressure on medicine prices; 
 currency volatility; and 
 market specific risks. 
 
6.3.3 Research question 3: What learnings can other companies take from 
the case study analysis of Aspen?  
  
The study identified the following key takeaways for other companies: 
 
 the importance of strategy and strategic leadership; 
 the value of organic growth; 
 the need to leverage core competencies to create a sustainable 
competitive advantage; 
 the importance of strategic fit and integration when acquiring products or 
businesses; and 
 the need to build from a solid base, select the right strategy and plan 
carefully when expanding internationally. 
 
6.4 A Model for Sustainable Growth 
 
The findings of the research and the answers to the research questions were used 
to identify key factors which other companies can use, particularly South African 
pharmaceutical companies, in their growth planning process. 
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These key factors were used to develop a model for sustainable growth, which is 

































































Starting at the bottom of the diagram, strategic leadership is identified as a critical 
input into the model.  At the core of the model is strategy.  The next level of the 
model is the identification or establishment of a core competence.  Through the 
development of this strategic capability a strategic advantage may be obtained. 
 
The next level of the model is organic growth which relies on new and existing 
products being provided to new and existing customers to increase revenue and 
generate profits.  The following level of the model provides for inorganic growth 
through the acquisition of products or businesses which are a strategic fit with the 
business and which are seamlessly integrated into the organisation.   
 
The final layer of the model is global expansion.  Working from a solid base and 
through careful planning, companies may focus on emerging markets and use 
glocalisation to expand the business into global territories.  In so doing, the 
company is provided with new markets, new customers and vast opportunities. 
 
The intended outcome of these elements and strategies is the sustainable growth 
of the company, as depicted at the top of the diagram. 
 
6.5 Limitations of the Study 
 
Chapter 3 sets out the research methodology adopted in this study and certain of 
the limitations in the approach followed were discussed.  A summary of the 
limitations of the study is set out below:   
 
 The use of a single case study may be criticised for being too narrow as 
the use of Aspen as a single case in the case study analysis limited the 
research.  Other South African pharmaceutical companies were not 
analysed or compared to Aspen and the growth of Aspen was not shown 
in context with its competitors. 
 
 The use of secondary data in the form of Aspen’s archival data, limited the 
researcher to information which was publicly available.  The possibility of 
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the reliability of such archival data being affected by the bias of its 
preparers may also have limited the study.   
 
 The use of a descriptive study, without proof of any causal relationship 
between events that occurred during the period under review and the 
growth of the company, limited the research and made inferential analysis 
difficult. 
 
 The analytic generalisation used to determine what learnings other 
companies can take from the case study analysis of Aspen was not 
conclusive (nor was it intended to be) and may thus be considered a 
limitation of the study.   
 
6.6 Recommendations for Future Research 
 
The identification of the study limitations provides a useful source of 
recommendations for future research. 
 
A study of more South African pharmaceutical companies, including the growth 
strategies adopted by them and the challenges faced by them, could highlight 
trends within this sector and enable a comparative analysis.   
 
A study may be conducted which supplements Aspen’s publicly available reports, 
being secondary data, with primary data.  For example, the use of interviews with 
Aspen’s key executives and top management may provide further insight into the 
subject.  Such interviews may provide valuable first-hand insight into the growth 
strategies adopted by Aspen and the challenges faced by the company. 
 
A statistical study of Aspen using more quantitative data and the testing of 
hypotheses could be used to study the strategies adopted and the growth of the 
company over the same period in order to determine whether a causal link existed 
between the two. 
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With regard to the analytic generalisation used to determine what learnings other 
companies can take from the case study analysis of Aspen, further research or 
case studies could investigate the propositions put forward in order to determine 
categorical findings and test whether a relationship exists between the suggested 




Through an aggressive growth strategy and a rapid global expansion strategy, 
Aspen has grown from a business in a suburban house in Durban, South Africa to 
a southern hemisphere pharmaceutical giant with its products reaching more than 
150 countries across the world.  This evolution of Aspen provided fascinating 
material for an MBA case study used to identify and analyse the growth strategies 
adopted by a global pharmaceutical company. 
 
As Aspen continues on its growth trajectory and builds on the foundation which it 
has laid in its transformation from a South African company to a truly global 
company, it is expected that the company will continue to be of great interest to 
competing pharmaceutical companies, investors, investment analysts and 
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The commencement of the business in Port Elizabeth, South Africa, which 
later became Lennon Limited, the originator company to the Aspen Group 
today 
1997 
Aspen Healthcare (Pty) Limited began trading with Stephen Saad (current 
Group Chief Executive) and Gus Attridge (current Deputy Group Chief 
Executive) as two of the four founding members 
1998 Listed on the JSE through reverse listing into Medhold Limited 
1999 Acquired the pharmaceutical business of South African Druggists for R2,4 billion in a hostile takeover 
2001 Aspen Australia commenced trade as a start-up operation 
2003 Entered into a fostering arrangement with GSK for the marketing and distribution of 40 branded products into the South African private sector 
2003 
 Aspen Stavudine was launched – Africa’s first generic ARV 
 Aspen became the first generic company globally to be accredited to 
the PEPFAR Fund (United States President’s Emergency Plan for AIDS 
Relief) 
 The US-based Clinton Foundation announced that it had selected 
Aspen, together with two other multinational companies, for the 
manufacture of ARVs 
2004 Acquired FCC, the only South African manufacturer of APIs 
2004 Acquired Infacare, the infant nutritional brand, from Dutch-based Royal Numico 
2004 Aspen’s multi-million Rand Port Elizabeth-based Unit 1 facility became operational 
2005 
Aspen’s Unit 1 facility in Port Elizabeth became the world’s first 
manufacturing site to receive tentative US FDA approval for the production 
of certain generic ARVs 
2006 
Secured distribution rights for a number of important ARVs from MSD, 
Bristol Myers Squibb, Roche and Tibotec as the Group extended its 
portfolio as the biggest supplier of ARVs in Africa 
2007 
Prestige Brands Incorporated entered into an agreement with Aspen for 
the supply of eye drops from Aspen’s sterile facility in Port Elizabeth to the 
US market 
142 
2008 Entered the Latin American market through an investment with Strides Acrolab Ltd in businesses established in Brazil, Mexico and Venezuela 
2008 Acquired 60% of the share capital of Shelys with businesses in Kenya, Tanzania and Uganda 
2008 
 Aspen Global, was set up to manage the intellectual property and 
commercial activities of Aspen’s international ventures 
 Aspen Global acquired the intellectual property rights to four GSK-
branded products for R2,7 billion, enabling Aspen to distribute these 
global brands, namely Eltroxin, Imuran, Lanoxin and Zyloric, to more 
than 100 countries 
2009 
Concluded a series of strategic transactions with GSK worth R4,6 billion 
comprising: 
- the acquisition of the rights to distribute GSK’s pharmaceutical 
products in South Africa,  
- the formation of The GSK Aspen Healthcare for Africa Collaboration 
in SSA to market and sell pharmaceuticals in SSA,  
- the acquisition of eight specialist branded products for worldwide 
distribution, and  
- the acquisition of a manufacturing site in Bad Oldesloe, Germany 
2009 
Aspen Healthcare FZ LLC, was set up in Dubai to manage and represent 
the global brands portfolio in the European, Middle Eastern, North African 
and Canadian (EMENAC) region 
2010 Aspen Asia Company Limited was established 
2010 Took full control of the Latin American businesses acquired in 2008 
2010 Beta Healthcare commenced with commercial production at its newly built pharmaceutical manufacturing facility in Nairobi 
2010 Revenue exceeded R10 billion for the first time 
2011 Acquired the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited, now Aspen Pharma (Pty) Limited, for R5,9 billion 
2012 For the first time in its history, profits from Aspen’s International businesses exceeded those generated by the South African business 
2012 Aspen Philippines Inc. began trading 
2012 Acquired a portfolio of established GSK OTC products in selected territories for R2,1 billion 
2013 The International business became the biggest contributor to Group revenue for the first time 
2013 Acquired a portfolio of 25 established prescription-branded products from GSK (“classic brands”) with distribution rights in Australia 
143 
2013 
Aspen Australia commenced the distribution of the leading infant nutritional 
products in that country following the acquisition of the rights to certain 
intellectual property licences and the related business by the Aspen Group 
2013 
 Aspen Healthcare Taiwan Ltd was established 
 Aspen Pharmacare Nigeria Limited began trading  
 Aspen Medical Products Malaysia SDN BHD began trading 
2013 
 Aspen was one of five South African companies named on the Boston 
Consulting Group’s 2013 list of “100 Global Challengers” companies 
from emerging markets that are “growing so quickly overseas that they 
are reshaping industries and surpassing many traditional multinational 
companies” 
 Aspen Pharmacare was ranked 10th in the Sunday Times’ Business 
Times 2012 Top 100 South African Companies, while Group Chief 
Executive Stephen Saad received the Sunday Times “Business Leader 
of the Year” award 
2014 
 Aspen was one of four South African companies included on the Boston 
Consulting Group’s 2014 list of “100 Global Challengers” companies 
from emerging markets that are “growing so quickly overseas that they 
are reshaping industries and surpassing many traditional multinational 
companies” 
 Aspen was ranked as the 10th most innovative company by Forbes’ 
“The Top 25 Most Innovative Companies in the World 2014” list (Forbes 
September 2014) 
 Aspen was ranked 10th in the top 100 companies over five years 
category and second in the top 40 index companies over five years in 
the 2013 Sunday Times “Top 100 Companies Awards” in South Africa 
2014 
Acquired an API business and a portfolio of branded finish dose form 
molecules from MSD as well as two branded injectable anticoagulants and 
a specialised sterile production site from GSK 
2014 
Established a number of additional offices across Europe, the CIS and in 
Latin America, increasing coverage to more than 50 locations across the 
world  
2014 Intellectual property rights in related infant nutritional businesses in Latin America and South Africa were acquired from Nestlé 
2014 Aspen Japan KK was established 
 








Selected Aspen acquisitions and divestments 2004 – 2014 
 
Financial 
year Acquisition Divestment 
2004 Acquired FCC, the only South African manufacturer of APIs  
2004 Acquired the Vinolia soap range (FMCG)  
2004 
Acquired Dutch-based Royal 
Numico’s South African baby 
food business, as well as the 
Infacare brand and their 




Acquired Mentadent P and 
secured a long-term agreement 
for Close-up from Unilever South 




Joint venture with Matrix 
Laboratories in terms of which 
Aspen acquired a 50% share in 
Astrix Laboratories Ltd, an ARV 
API manufacturing facility in India 
Joint venture with Matrix 
Laboratories in terms of which 
50% of the FCC business was 
sold to Matrix 
2008  Divested of its nutraceutical range 
2008  Divested of 51% in the UK-based Co-pharma Ltd 
2008 
Transactions were entered into 
with Strides Acrolab Ltd to 
acquire 50% (subsequently an 
additional 1% stake was acquired 
by Aspen) of its joint ventures in 
Latin America (Brazil, Mexico and 
Venezuela) and 50% of an 
oncology development and 





Concluded a deal for the 
acquisition of 60% of Shelys 
Africa Ltd, with operations in East 





year Acquisition Divestment 
2008 
Acquired four branded products 
from GSK for R2,7 billion for 
distribution of these global brands 
to more than 100 countries 
 
2009 
Termination of the Matrix 
Laboratories Ltd joint venture 
(Aspen acquired remaining 50% 
share in FCC gaining full control) 
Termination of the Matrix 
Laboratories Ltd joint venture 
(Aspen disposed of its 50% share 
in Astrix Laboratories Ltd) 
2009 
 Acquisition of the rights to 
distribute GSK’s 
pharmaceutical products in 
South Africa (45 GSK 
brands) 
 Acquisition of eight 
specialist, branded products 
from GSK for worldwide 
distribution 
 Acquisition of GSK’s 
manufacturing facility in Bad 
Oldesloe, Germany 
 
2009  Divested of its business in the USA 
2010  
Disposed to Strides Arcolab Ltd  
the Campos facility and related 
products in Brazil as well as 
Aspen’s 50% share in the 
oncology joint ventures  
2011 
Acquired the pharmaceutical 
business of Australian-based 
Sigma Pharmaceuticals Limited, 
now Aspen Pharma (Pty) Limited, 
for R5,9 billion (including 
branded, OTC and a consumer 




Disposed of remaining 49% 
investment in UK-based Co-
pharma Ltd 
2011  
Disposed of Vinolia, Playboy and 
Playgirl ranges and certain 
Formule Naturelle products  
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Financial 
year Acquisition Divestment 
2012  
Disposed of the Mentadent P 
brand and cancelled the 
unexpired portion of the Close-Up 
licence 
2012 
Acquired the 40% minority 
shareholding in Shelys resulting 
in the company and its 
subsidiaries becoming wholly 
owned subsidiaries of Aspen 
(Kenya, Tanzania and Uganda) 
 
2012 
Acquired a portfolio of 
established OTC products from 




Acquired a portfolio of 25 
branded pharmaceutical products 




Acquired the rights to intellectual 
property licences and related 
businesses in infant nutrition, in 
Australia and certain southern 
African territories (including 




Acquired certain licence rights to 
infant nutritional intellectual 
property, including a production 
facility in Mexico, and shares in 
infant nutritional businesses in 
several countries in Latin 
America from Nestlé for a 




Acquired an API manufacturing 
business, primarily in the 
Netherlands with a satellite 
operation in the United States, 
from MSD for approximately 





year Acquisition Divestment 
2014 
Acquired a portfolio of 11 
branded finished dose form 




 Acquired the Arixtra and 
Fraxiparine / Fraxodi 
thrombolytic brands 
worldwide (excluding China, 
India and Pakistan) from 
GSK for GBP505 million 
 Acquired the specialised 
sterile production site in 
France, which manufactures 
the above brands, from GSK 
for GBP194 million 
 
 















Aspen growth in numbers 2004 – 2014 
 
 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Revenue 
(R’million) 2 201,7 2 814,6 3 449,3 4 025,9 4 682,5 8 441,4 9 619,2 12 383,2 15 255,8 19 308,0 29 515,1 
Operating profit 














4 788,1 9 005,3 14 102,9 14 413,9 12 444,7 19 783,7 32 845,6 36 480,8 57 234,0 103 484,6 136 395,8 
Share price at 
year-end 
(R) 
12.70 23.80 36.50 37.00 31.80 54.75 76.10 84.00 125.85 227.07 298.89 
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 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
Cash flow from 
capital 
expenditure – 
property, plant & 
equipment 
(R’million) 
(158,6) (81,1) (174,6) (287,7) (379,3) (626,7) (632,0) (651,5) (469,6) (667,1) (1 328,9) 





(90,6) (93,4) (132,4) (147,0) (166,0) (3 279,9) (660,5) (188,7) (2 148,8) (3 654,9) (700,4) 





(50,3) (262,1) (267,6) (0,1) (1 357,5) 102,9 33,4 (5 893,2) (315,6) (1 578,6) (19 764,2) 
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